1	Of	of	IN	_	2	case
2	note	note	NN	_	19	nmod
3	,	,	,	_	19	punct
4	however	however	RB	_	19	advmod
5	,	,	,	_	19	punct
6	GALNT2	galnt2	NN	_	7	compound
7	drug1	drug1	NN	_	19	nsubj
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	previously	previously	RB	_	10	advmod
10	associated	associate	VBN	_	7	dep
11	with	with	IN	_	15	case
12	high-density	high-density	JJ	_	15	amod
13	lipoprotein	lipoprotein	NN	_	15	compound
14	cholesterol	cholesterol	NN	_	15	compound
15	levels	level	NNS	_	10	nmod
16	in	in	IN	_	17	case
17	EA	ea	NN	_	15	nmod
18	-RRB-	-rrb-	-RRB-	_	10	punct
19	had	have	VBD	_	0	ROOT
20	multiple	multiple	JJ	_	24	amod
21	potentially	potentially	RB	_	22	advmod
22	novel	novel	JJ	_	24	amod
23	PheWAS	phewas	NN	_	24	compound
24	associations	association	NNS	_	19	dobj
25	,	,	,	_	19	punct
26	with	with	IN	_	29	case
27	hypertension	hypertension	NN	_	29	compound
28	related	related	JJ	_	29	amod
29	phenotypes	phenotype	NNS	_	19	nmod
30	in	in	IN	_	31	case
31	AA	aa	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	with	with	IN	_	36	case
34	serum	serum	NN	_	36	compound
35	calcium	calcium	NN	_	36	compound
36	levels	level	NNS	_	31	conj
37	and	and	CC	_	36	cc
38	drug2	drug2	NN	_	39	compound
39	phenotypes	phenotype	NNS	_	36	conj
40	in	in	IN	_	41	case
41	EA	ea	NN	_	36	nmod
42	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	majority	majority	NN	_	12	nsubj
3	of	of	IN	_	7	case
4	the	the	DT	_	7	det
5	potentially	potentially	RB	_	6	advmod
6	novel	novel	JJ	_	7	amod
7	results	result	NNS	_	2	nmod
8	were	be	VBD	_	12	cop
9	for	for	IN	_	12	case
10	single	single	JJ	_	12	amod
11	PheWAS	phewas	NN	_	12	compound
12	phenotype-classes	phenotype-class	NNS	_	0	ROOT
13	,	,	,	_	12	punct
14	for	for	IN	_	15	case
15	example	example	NN	_	12	nmod
16	,	,	,	_	12	punct
17	for	for	IN	_	19	case
18	CDKN2A/B	cdkn2a/b	NN	_	19	compound
19	drug1	drug1	NN	_	12	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	previously	previously	RB	_	22	advmod
22	associated	associate	VBN	_	19	dep
23	with	with	IN	_	26	case
24	type	type	NN	_	26	compound
25	2	2	CD	_	26	nummod
26	drug2	drug2	NN	_	22	nmod
27	in	in	IN	_	28	case
28	EA	ea	NN	_	26	nmod
29	-RRB-	-rrb-	-RRB-	_	22	punct
30	a	a	DT	_	32	det
31	PheWAS	phewas	NN	_	32	compound
32	association	association	NN	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	identified	identify	VBN	_	19	acl:relcl
35	for	for	IN	_	37	case
36	hemoglobin	hemoglobin	NN	_	37	compound
37	levels	level	NNS	_	34	nmod
38	in	in	IN	_	39	case
39	AA	aa	NN	_	37	nmod
40	.	.	.	_	12	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	root
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	:	:	:	_	4	punct
8	C	c	NN	_	10	compound
9	>	>	JJR	_	10	amod
10	G	g	NN	_	28	nsubjpass
11	in	in	IN	_	13	case
12	INK4	ink4	NN	_	13	compound
13	locus	locus	NN	_	10	nmod
14	in	in	IN	_	17	case
15	familial	familial	JJ	_	17	amod
16	drug2	drug2	NN	_	17	compound
17	patients	patient	NNS	_	10	nmod
18	and	and	CC	_	10	cc
19	on	on	IN	_	21	case
20	lipid	lipid	NN	_	21	compound
21	profile	profile	NN	_	10	conj
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	patients	patient	NNS	_	21	nmod
25	has	have	VBZ	_	28	aux
26	not	not	RB	_	28	neg
27	been	be	VBN	_	28	auxpass
28	studied	study	VBN	_	4	dep
29	in	in	IN	_	30	case
30	Pakistan	Pakistan	NNP	_	28	nmod
31	.	.	.	_	4	punct

1	An	a	DT	_	3	det
2	epistatic	epistatic	JJ	_	3	amod
3	interaction	interaction	NN	_	22	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	OR	or	NN	_	7	dep
10	1.56	1.56	CD	_	9	nummod
11	,	,	,	_	9	punct
12	p	p	NN	_	13	nsubj
13	=	=	JJ	_	9	dep
14	1.19	1.19	CD	_	16	nummod
15	*	*	SYM	_	16	dep
16	10	10	CD	_	13	dobj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	-2	-2	CD	_	13	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	-RRB-	-rrb-	-RRB-	_	9	punct
21	was	be	VBD	_	22	auxpass
22	found	find	VBN	_	0	ROOT
23	especially	especially	RB	_	25	advmod
24	in	in	IN	_	25	case
25	presence	presence	NN	_	22	nmod
26	of	of	IN	_	28	case
27	drug3	drug3	NN	_	28	compound
28	disease	disease	NN	_	25	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	OR	or	NN	_	31	nsubj
31	=	=	JJ	_	22	parataxis
32	2.15	2.15	CD	_	31	dobj
33	,	,	,	_	31	punct
34	p	p	NN	_	35	nsubj
35	=	=	JJ	_	31	parataxis
36	3.12	3.12	CD	_	38	nummod
37	*	*	SYM	_	38	dep
38	10	10	CD	_	35	dobj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	-4	-4	CD	_	31	dep
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	-RRB-	-rrb-	-RRB-	_	31	punct
43	.	.	.	_	22	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	longitudinal	longitudinal	JJ	_	4	amod
4	study	study	NN	_	27	nmod
5	with	with	IN	_	7	case
6	11	11	CD	_	7	nummod
7	years	year	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	follow-up	follow-up	NN	_	7	nmod
10	on	on	IN	_	11	case
11	survival	survival	NN	_	9	nmod
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	oldest-old	oldest-old	JJ	_	15	amod
15	Danes	Danes	NNP	_	11	nmod
16	,	,	,	_	27	punct
17	only	only	RB	_	18	advmod
18	one	one	CD	_	19	nummod
19	SNP	snp	NN	_	27	nsubj
20	,	,	,	_	19	punct
21	drug1	drug1	NN	_	19	appos
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	IL6	il6	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	19	punct
26	was	be	VBD	_	27	cop
27	borderline	borderline	JJ	_	0	ROOT
28	significantly	significantly	RB	_	29	advmod
29	associated	associate	VBN	_	27	acl
30	with	with	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	from	from	IN	_	33	case
33	age	age	NN	_	31	nmod
34	92	92	CD	_	33	nummod
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	P-corrected	p-corrected	JJ	_	37	nsubj
37	=	=	JJ	_	31	dep
38	0.064	0.064	CD	_	37	dobj
39	-RRB-	-rrb-	-RRB-	_	37	punct
40	.	.	.	_	27	punct

1	Haplotypes	haplotype	NNS	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	or	or	CC	_	3	cc
7	drug3	drug3	NN	_	3	conj
8	and	and	CC	_	3	cc
9	drug4	drug4	NN	_	3	conj
10	revealed	reveal	VBD	_	0	ROOT
11	an	a	DT	_	12	det
12	association	association	NN	_	10	dobj
13	with	with	IN	_	15	case
14	drug5	drug5	NN	_	15	compound
15	cancer	cancer	NN	_	12	nmod
16	which	which	WDT	_	19	nsubj
17	was	be	VBD	_	19	cop
18	significantly	significantly	RB	_	19	advmod
19	stronger	stronger	JJR	_	12	acl:relcl
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	homozygous	homozygous	JJ	_	23	amod
23	carriers	carrier	NNS	_	19	nmod
24	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	nonsynonymous	nonsynonymous	JJ	_	4	amod
3	OPRM1	oprm1	NN	_	4	compound
4	drug1	drug1	NN	_	9	nsubj
5	might	might	MD	_	9	aux
6	be	be	VB	_	9	cop
7	a	a	DT	_	9	det
8	risk	risk	NN	_	9	compound
9	factor	factor	NN	_	0	ROOT
10	for	for	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	to	to	TO	_	13	case
13	opioids	opioid	NNS	_	11	nmod
14	or	or	CC	_	13	cc
15	heroin	heroin	NN	_	13	conj
16	in	in	IN	_	19	case
17	an	a	DT	_	19	det
18	Asian	asian	JJ	_	19	amod
19	population	population	NN	_	9	nmod
20	.	.	.	_	9	punct

1	No	no	DT	_	2	neg
2	association	association	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	between	between	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	phenotypes	phenotype	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	incidence	incidence	NN	_	7	dep
10	,	,	,	_	9	punct
11	intensity	intensity	NN	_	9	conj
12	,	,	,	_	9	punct
13	and	and	CC	_	9	cc
14	duration	duration	NN	_	9	conj
15	-RRB-	-rrb-	-RRB-	_	9	punct
16	and	and	CC	_	7	cc
17	different	different	JJ	_	19	amod
18	drug1	drug1	NN	_	19	compound
19	genotypes	genotype	NNS	_	7	conj
20	.	.	.	_	4	punct

1	Results	result	NNS	_	2	nsubj
2	revealed	reveal	VBD	_	0	ROOT
3	an	a	DT	_	4	det
4	association	association	NN	_	2	dobj
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	cocaine	cocaine	NN	_	6	conj
9	and	and	CC	_	6	cc
10	heroin	heroin	NN	_	11	compound
11	drug2	drug2	NN	_	6	conj
12	in	in	IN	_	14	case
13	European	european	JJ	_	14	amod
14	Americans	american	NNS	_	4	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	p	p	NN	_	17	nsubj
17	=	=	JJ	_	4	dep
18	0.02	0.02	CD	_	17	dobj
19	;	;	:	_	17	punct
20	95	95	CD	_	21	nummod
21	%	%	NN	_	17	dep
22	C.I.	C.I.	NNP	_	21	dep
23	0.47	0.47	CD	_	22	nummod
24	-LSB-	-lsb-	-LRB-	_	26	punct
25	0.24-0	0.24-0	CD	_	26	nummod
26	.92	.92	CD	_	22	dep
27	-RSB-	-rsb-	-RRB-	_	26	punct
28	-RRB-	-rrb-	-RRB-	_	17	punct

1	The	the	DT	_	3	det
2	118G	118g	NN	_	3	compound
3	allele	allele	NN	_	4	nsubj
4	conferred	confer	VBD	_	0	ROOT
5	5.3-fold	5.3-fold	RB	_	6	advmod
6	increased	increase	VBN	_	7	amod
7	odds	odds	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	/	/	:	_	9	punct
11	drug3	drug3	NN	_	9	dep
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	p	p	NN	_	14	dep
14	<	<	JJR	_	9	dep
15	0.05	0.05	CD	_	14	nummod
16	-RRB-	-rrb-	-RRB-	_	14	punct
17	,	,	,	_	4	punct
18	while	while	IN	_	25	mark
19	the	the	DT	_	22	det
20	drug1	drug1	NN	_	22	compound
21	variant	variant	JJ	_	22	amod
22	allele	allele	NN	_	25	nsubjpass
23	was	be	VBD	_	25	auxpass
24	not	not	RB	_	25	neg
25	associated	associate	VBN	_	4	advcl
26	with	with	IN	_	27	case
27	drug4	drug4	NN	_	25	nmod
28	/	/	:	_	4	punct
29	drug5	drug5	NN	_	4	dep

1	In	in	IN	_	4	case
2	this	this	DT	_	4	det
3	meta	meta	NN	_	4	compound
4	analysis	analysis	NN	_	7	nmod
5	,	,	,	_	7	punct
6	we	we	PRP	_	7	nsubj
7	assessed	assess	VBD	_	0	ROOT
8	10	10	CD	_	10	nummod
9	case-control	case-control	JJ	_	10	amod
10	studies	study	NNS	_	11	nsubj
11	included	include	VBD	_	7	ccomp
12	7,067	7,067	CD	_	13	nummod
13	cases	case	NNS	_	11	dobj
14	and	and	CC	_	13	cc
15	9,374	9,374	CD	_	16	nummod
16	controls	control	NNS	_	13	conj
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	association	association	NN	_	13	nmod
20	between	between	IN	_	22	case
21	CYP1B1	cyp1b1	NN	_	22	compound
22	SNPs	snp	NNS	_	19	nmod
23	of	of	IN	_	24	case
24	Leu432Val	leu432val	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	drug1	drug1	NN	_	24	dep
27	,	,	,	_	26	punct
28	432C	432c	NN	_	30	compound
29	>	>	JJR	_	30	amod
30	G	g	NN	_	26	appos
31	-RRB-	-rrb-	-RRB-	_	26	punct
32	,	,	,	_	24	punct
33	Asn453Ser	asn453ser	NN	_	24	conj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug2	drug2	NN	_	33	dep
36	,	,	,	_	35	punct
37	453A	453a	NN	_	39	compound
38	>	>	JJR	_	39	amod
39	G	g	NN	_	35	appos
40	-RRB-	-rrb-	-RRB-	_	35	punct
41	,	,	,	_	24	punct
42	Ala119Ser	ala119ser	NN	_	24	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug3	drug3	NN	_	42	dep
45	,	,	,	_	44	punct
46	119G	119g	NN	_	48	compound
47	>	>	JJR	_	48	dep
48	T	t	NN	_	44	appos
49	-RRB-	-rrb-	-RRB-	_	44	punct
50	,	,	,	_	24	punct
51	Arg48Gly	arg48gly	NN	_	24	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	drug4	drug4	NN	_	51	dep
54	,	,	,	_	53	punct
55	48C	48c	NN	_	57	compound
56	>	>	JJR	_	57	amod
57	G	g	NN	_	53	appos
58	-RRB-	-rrb-	-RRB-	_	53	punct
59	and	and	CC	_	24	cc
60	the	the	DT	_	61	det
61	risk	risk	NN	_	24	conj
62	of	of	IN	_	63	case
63	drug5	drug5	NN	_	61	nmod
64	.	.	.	_	7	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	our	we	PRP$	_	6	nmod:poss
5	human	human	JJ	_	6	amod
6	study	study	NN	_	1	nmod
7	,	,	,	_	6	punct
8	the	the	DT	_	12	det
9	A118G	a118g	NN	_	12	compound
10	singlenucleotide	singlenucleotide	NN	_	12	compound
11	polymorphism	polymorphism	NN	_	12	compound
12	drug1	drug1	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	associated	associate	VBN	_	6	acl:relcl
15	with	with	IN	_	19	case
16	drug2	drug2	NN	_	19	compound
17	virus	virus	NN	_	19	compound
18	disease	disease	NN	_	19	compound
19	severity	severity	NN	_	14	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	p	p	NN	_	22	nsubj
22	=	=	JJ	_	19	dep
23	0.015	0.015	CD	_	22	dobj
24	-RRB-	-rrb-	-RRB-	_	22	punct
25	.	.	.	_	1	punct

1	Compared	compare	VBN	_	3	case
2	to	to	TO	_	3	case
3	controls	control	NNS	_	13	advcl
4	,	,	,	_	13	punct
5	drug3	drug3	NN	_	6	compound
6	patients	patient	NNS	_	13	nsubj
7	-LRB-	-lrb-	-LRB-	_	11	punct
8	with	with	IN	_	11	case
9	and	and	CC	_	11	cc
10	without	without	IN	_	11	case
11	drug4	drug4	NN	_	6	nmod
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	showed	show	VBD	_	0	ROOT
14	significantly	significantly	RB	_	15	advmod
15	increased	increase	VBN	_	16	amod
16	frequency	frequency	NN	_	13	dobj
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	DBH	dbh	NN	_	16	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug1	drug1	NN	_	19	dep
22	:	:	:	_	21	punct
23	OR	or	NN	_	21	dep
24	1.73	1.73	CD	_	23	nummod
25	;	;	:	_	21	punct
26	CI	ci	NN	_	21	dep
27	1.15-2	1.15-2	CD	_	28	compound
28	.59	.59	CD	_	26	nummod
29	;	;	:	_	21	punct
30	P	p	NN	_	31	nsubj
31	=	=	JJ	_	21	dep
32	0.008	0.008	CD	_	31	dobj
33	-RRB-	-rrb-	-RRB-	_	21	punct
34	and	and	CC	_	16	cc
35	the	the	DT	_	38	det
36	OPRM1	oprm1	NN	_	38	compound
37	risk	risk	NN	_	38	compound
38	genotypes	genotype	NNS	_	16	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug2	drug2	NN	_	38	dep
41	:	:	:	_	40	punct
42	OR	or	NN	_	40	dep
43	1.71	1.71	CD	_	42	nummod
44	;	;	:	_	40	punct
45	CI	ci	NN	_	40	dep
46	1.17-2	1.17-2	CD	_	47	compound
47	.50	.50	CD	_	45	nummod
48	;	;	:	_	40	punct
49	P	p	NN	_	50	nsubj
50	=	=	JJ	_	40	dep
51	0.006	0.006	CD	_	50	dobj
52	-RRB-	-rrb-	-RRB-	_	40	punct
53	.	.	.	_	13	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	present	present	JJ	_	4	amod
4	study	study	NN	_	6	nmod
5	we	we	PRP	_	6	nsubj
6	investigated	investigate	VBD	_	0	ROOT
7	whether	whether	IN	_	12	mark
8	the	the	DT	_	10	det
9	drug1	drug1	NN	_	10	compound
10	SNP	snp	NN	_	12	nsubj
11	could	could	MD	_	12	aux
12	predict	predict	VB	_	6	ccomp
13	clinical	clinical	JJ	_	14	amod
14	outcome	outcome	NN	_	12	dobj
15	regarding	regard	VBG	_	16	case
16	progression	progression	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	disability	disability	NN	_	18	conj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	16	nmod
23	with	with	IN	_	25	case
24	low	low	JJ	_	25	amod
25	drug3	drug3	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	drug4	drug4	NN	_	25	conj
28	after	after	IN	_	30	case
29	drug5	drug5	NN	_	30	compound
30	herniation	herniation	NN	_	22	nmod
31	.	.	.	_	6	punct

1	Earlier	earlier	JJR	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	22	mark
6	the	the	DT	_	10	det
7	single	single	JJ	_	10	amod
8	nucleotide	nucleotide	NN	_	10	compound
9	polymorphism	polymorphism	NN	_	10	compound
10	drug1	drug1	NN	_	22	nsubj
11	in	in	IN	_	15	case
12	the	the	DT	_	15	det
13	opioid	opioid	JJ	_	15	amod
14	receptor	receptor	NN	_	15	compound
15	mu	mu	NN	_	22	nmod
16	1	1	CD	_	15	nummod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	OPRM1	oprm1	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	gene	gene	NN	_	22	nsubj
21	may	may	MD	_	22	aux
22	affect	affect	VB	_	4	ccomp
23	drug2	drug2	NN	_	22	dobj
24	.	.	.	_	4	punct

1	Individuals	individual	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	genotyped	genotype	VBN	_	0	ROOT
4	for	for	IN	_	6	case
5	PCSK9	pcsk9	NN	_	6	compound
6	R46L	r46l	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	ABCG8	abcg8	NN	_	12	compound
12	D19H	d19h	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug2	drug2	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	6	punct
17	and	and	CC	_	6	cc
18	APOE	APOE	NNP	_	19	compound
19	R112C	r112c	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug3	drug3	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	and	and	CC	_	19	cc
24	R158C	r158c	NN	_	26	compound
25	drug4	drug4	NN	_	26	compound
26	polymorphisms	polymorphism	NNS	_	19	conj
27	,	,	,	_	6	punct
28	all	all	DT	_	32	nsubjpass
29	of	of	IN	_	30	case
30	which	which	WDT	_	28	nmod
31	are	be	VBP	_	32	auxpass
32	associated	associate	VBN	_	6	acl:relcl
33	with	with	IN	_	34	case
34	drug5	drug5	NN	_	32	nmod

1	Male	male	JJ	_	2	amod
2	children	child	NNS	_	7	nsubj
3	of	of	IN	_	4	case
4	alcoholics	alcoholic	NNS	_	2	nmod
5	were	be	VBD	_	7	cop
6	less	less	RBR	_	7	advmod
7	likely	likely	JJ	_	0	ROOT
8	to	to	TO	_	10	mark
9	be	be	VB	_	10	cop
10	carriers	carrier	NNS	_	7	xcomp
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	G	g	NN	_	14	compound
14	allele	allele	NN	_	10	nmod
15	in	in	IN	_	19	case
16	single	single	JJ	_	19	amod
17	nucleotide	nucleotide	NN	_	19	compound
18	polymorphism	polymorphism	NN	_	19	compound
19	A118G	a118g	NN	_	14	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug1	drug1	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	,	,	,	_	7	punct
24	and	and	CC	_	7	cc
25	those	those	DT	_	35	nsubj
26	who	who	WP	_	28	nsubj
27	were	be	VBD	_	28	cop
28	homozygous	homozygous	JJ	_	25	acl:relcl
29	for	for	IN	_	32	case
30	the	the	DT	_	32	det
31	A	a	NN	_	32	compound
32	allele	allele	NN	_	28	nmod
33	were	be	VBD	_	35	cop
34	more	more	RBR	_	35	advmod
35	likely	likely	JJ	_	7	conj
36	to	to	TO	_	37	case
37	affiliate	affiliate	NN	_	35	nmod
38	with	with	IN	_	40	case
39	alcohol	alcohol	NN	_	40	compound
40	use	use	NN	_	37	nmod
41	promoting	promote	VBG	_	40	acl
42	peers	peer	NNS	_	41	dobj
43	who	who	WP	_	44	nsubj
44	increased	increase	VBD	_	42	acl:relcl
45	the	the	DT	_	46	det
46	risk	risk	NN	_	44	dobj
47	for	for	IN	_	49	case
48	drug2	drug2	NN	_	49	compound
49	symptoms	symptom	NNS	_	46	nmod
50	at	at	IN	_	52	case
51	all	all	DT	_	52	det
52	ages	age	NNS	_	44	nmod
53	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	COMT	COMT	NNP	_	5	compound
3	drug1	drug1	NN	_	5	compound
4	gene	gene	NN	_	5	compound
5	polymorphism	polymorphism	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	investigated	investigate	VBN	_	0	ROOT
9	as	as	IN	_	12	case
10	a	a	DT	_	12	det
11	susceptibility	susceptibility	NN	_	12	compound
12	factor	factor	NN	_	8	nmod
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	8	punct

1	No	no	DT	_	4	neg
2	statistically	statistically	RB	_	4	advmod
3	significant	significant	JJ	_	4	amod
4	results	result	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	meta-analysis	meta-analysis	NN	_	6	nmod
9	but	but	CC	_	6	cc
10	one	one	CD	_	11	nummod
11	study	study	NN	_	12	nsubj
12	reported	report	VBD	_	6	conj
13	that	that	IN	_	18	mark
14	the	the	DT	_	16	det
15	drug1	drug1	NN	_	16	compound
16	allele	allele	NN	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	associated	associate	VBN	_	12	ccomp
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	COMT	COMT	NNP	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	7	nsubjpass
5	was	be	VBD	_	7	auxpass
6	also	also	RB	_	7	advmod
7	found	find	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	modulate	modulate	VB	_	7	xcomp
10	drug2	drug2	NN	_	9	dobj
11	in	in	IN	_	13	case
12	normal	normal	JJ	_	13	amod
13	people	people	NNS	_	9	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	7	punct

1	Whites	whites	NNS	_	17	nsubj
2	with	with	IN	_	4	case
3	allele	allele	NN	_	4	compound
4	G	g	NN	_	1	nmod
5	of	of	IN	_	9	case
6	the	the	DT	_	9	det
7	functional	functional	JJ	_	9	amod
8	polymorphism	polymorphism	NN	_	9	compound
9	118A	118a	NN	_	4	nmod
10	>	>	JJR	_	15	amod
11	G	g	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	reference	reference	NN	_	15	compound
14	sequence	sequence	NN	_	15	compound
15	drug1	drug1	NN	_	9	dep
16	-RRB-	-rrb-	-RRB-	_	1	punct
17	showed	show	VBD	_	0	ROOT
18	a	a	DT	_	20	det
19	smaller	smaller	JJR	_	20	amod
20	decrease	decrease	NN	_	17	dobj
21	in	in	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	;	;	:	_	17	punct
24	those	those	DT	_	40	nsubj
25	bearing	bear	VBG	_	24	acl
26	minor	minor	JJ	_	28	amod
27	alleles	allele	NNS	_	28	compound
28	IVS1	ivs1	NN	_	25	dobj
29	+	+	CC	_	28	cc
30	1050A	1050a	NN	_	28	conj
31	,	,	,	_	24	punct
32	IVS1	ivs1	NN	_	24	conj
33	+	+	CC	_	32	cc
34	14123A	14123a	NN	_	32	conj
35	,	,	,	_	24	punct
36	and	and	CC	_	24	cc
37	IVS2	ivs2	NN	_	24	conj
38	+	+	CC	_	37	cc
39	31A	31a	NN	_	37	conj
40	showed	show	VBD	_	17	parataxis
41	a	a	DT	_	43	det
42	larger	larger	JJR	_	43	amod
43	decrease	decrease	NN	_	40	dobj
44	in	in	IN	_	45	case
45	drug3	drug3	NN	_	43	nmod
46	over	over	IN	_	48	case
47	interval	interval	NN	_	48	compound
48	X	x	NN	_	43	nmod
49	-LRB-	-lrb-	-LRB-	_	43	punct
50	0.01	0.01	CD	_	49	root
51	<	<	JJR	_	50	amod
52	P	p	NN	_	51	dep
53	<	<	JJR	_	52	amod
54	.05	.05	CD	_	53	dep
55	-RRB-	-rrb-	-RRB-	_	50	punct

1	Conflicting	conflicting	JJ	_	2	amod
2	results	result	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	role	role	NN	_	4	nmod
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	mu-opioid	mu-opioid	JJ	_	11	amod
11	receptor	receptor	NN	_	7	nmod
12	-LRB-	-lrb-	-LRB-	_	16	punct
13	OPRM1	oprm1	NN	_	16	compound
14	-RRB-	-rrb-	-RRB-	_	16	punct
15	polymorphism	polymorphism	NN	_	16	compound
16	A118G	a118g	NN	_	11	dep
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	Asn40Asp	asn40asp	NN	_	16	dep
19	,	,	,	_	18	punct
20	drug1	drug1	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	development	development	NN	_	16	nmod
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	4	punct

1	drug3	drug3	NN	_	4	nsubj
2	were	be	VBD	_	4	cop
3	more	more	RBR	_	4	advmod
4	sensitive	sensitive	JJ	_	0	ROOT
5	to	to	TO	_	7	case
6	experimental	experimental	JJ	_	7	amod
7	pain	pain	NN	_	4	nmod
8	than	than	IN	_	10	case
9	healthy	healthy	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	4	nmod
11	and	and	CC	_	4	cc
12	,	,	,	_	17	punct
13	in	in	IN	_	14	case
14	particular	particular	JJ	_	17	nmod
15	,	,	,	_	17	punct
16	drug4	drug4	JJ	_	17	amod
17	individuals	individual	NNS	_	4	conj
18	with	with	IN	_	21	case
19	the	the	DT	_	21	det
20	met/met	met/met	NN	_	21	compound
21	genotype	genotype	NN	_	17	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	drug1	drug1	NN	_	24	compound
24	SNP	snp	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	or	or	CC	_	21	cc
27	the	the	DT	_	29	det
28	HPS-APS	hps-aps	NN	_	29	compound
29	haplotypes	haplotype	NNS	_	21	conj
30	showing	show	VBG	_	29	acl
31	higher	higher	JJR	_	33	amod
32	drug5	drug5	NN	_	33	compound
33	stimuli	stimulus	NNS	_	30	dobj
34	than	than	IN	_	35	case
35	patients	patient	NNS	_	33	nmod
36	carrying	carry	VBG	_	35	acl
37	the	the	DT	_	39	det
38	LPS	lps	NN	_	39	compound
39	haplotype	haplotype	NN	_	36	dobj
40	or	or	CC	_	39	cc
41	val	val	NN	_	42	compound
42	alleles	allele	NNS	_	39	conj
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	drug2	drug2	NN	_	45	compound
45	NP	np	NN	_	42	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	.	.	.	_	4	punct

1	According	accord	VBG	_	4	case
2	with	with	IN	_	4	case
3	previous	previous	JJ	_	4	amod
4	research	research	NN	_	8	nmod
5	,	,	,	_	8	punct
6	our	we	PRP$	_	7	nmod:poss
7	findings	finding	NNS	_	8	nsubj
8	revealed	reveal	VBD	_	0	ROOT
9	that	that	IN	_	20	mark
10	haplotypes	haplotype	NNS	_	20	nsubj
11	of	of	IN	_	15	case
12	the	the	DT	_	15	det
13	COMT	COMT	NNP	_	15	compound
14	geneand	geneand	NN	_	15	compound
15	genotypes	genotype	NNS	_	10	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	drug1	drug1	NN	_	19	compound
19	polymorphism	polymorphism	NN	_	15	nmod
20	play	play	VBP	_	8	ccomp
21	a	a	DT	_	23	det
22	key	key	JJ	_	23	amod
23	role	role	NN	_	20	dobj
24	on	on	IN	_	26	case
25	pain	pain	NN	_	26	compound
26	sensitivity	sensitivity	NN	_	20	nmod
27	in	in	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	8	punct

1	we	we	PRP	_	2	nsubj
2	assessed	assess	VBD	_	0	ROOT
3	10	10	CD	_	5	nummod
4	case-control	case-control	JJ	_	5	amod
5	studies	study	NNS	_	6	nsubj
6	included	include	VBD	_	2	ccomp
7	7,067	7,067	CD	_	8	nummod
8	cases	case	NNS	_	6	dobj
9	and	and	CC	_	8	cc
10	9,374	9,374	CD	_	11	nummod
11	controls	control	NNS	_	8	conj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	association	association	NN	_	8	nmod
15	between	between	IN	_	17	case
16	CYP1B1	cyp1b1	NN	_	17	compound
17	SNPs	snp	NNS	_	14	nmod
18	of	of	IN	_	22	case
19	Leu432Val	leu432val	JJ	_	22	amod
20	drug1	drug1	NN	_	22	compound
21	Asn453Ser	asn453ser	NN	_	22	compound
22	drug2	drug2	NN	_	17	nmod
23	,	,	,	_	17	punct
24	Ala119Ser	ala119ser	NN	_	25	compound
25	drug3	drug3	NN	_	17	appos
26	,	,	,	_	17	punct
27	drug4	drug4	NN	_	28	nsubj
28	nd	nd	VBD	_	17	acl:relcl
29	the	the	DT	_	30	det
30	risk	risk	NN	_	28	dobj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	.	.	.	_	2	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	6	mark
5	there	there	EX	_	6	expl
6	is	be	VBZ	_	3	ccomp
7	no	no	DT	_	9	neg
8	direct	direct	JJ	_	9	amod
9	effect	effect	NN	_	6	nsubj
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	genotype	genotype	NN	_	9	nmod
13	on	on	IN	_	15	case
14	the	the	DT	_	15	det
15	risk	risk	NN	_	9	nmod
16	for	for	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	among	among	IN	_	21	case
19	active	active	JJ	_	21	amod
20	heroin	heroin	NN	_	21	compound
21	users	user	NNS	_	17	nmod
22	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	0	ROOT
3	aimed	aim	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	investigate	investigate	VB	_	3	xcomp
6	associations	association	NNS	_	5	dobj
7	between	between	IN	_	9	case
8	subjective	subjective	JJ	_	9	amod
9	response	response	NN	_	6	nmod
10	to	to	TO	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	genetic	genetic	JJ	_	14	amod
14	polymorphisms	polymorphism	NNS	_	11	conj
15	and	and	CC	_	11	cc
16	haplotypes	haplotype	NNS	_	11	conj
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	u-opioid	u-opioid	JJ	_	20	amod
20	receptor	receptor	NN	_	9	nmod
21	including	include	VBG	_	25	case
22	the	the	DT	_	25	det
23	exonic	exonic	JJ	_	25	amod
24	variant	variant	JJ	_	25	amod
25	drug1	drug1	NN	_	20	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	Asp40Asn	asp40asn	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	study	study	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	focused	focus	VBN	_	0	ROOT
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	relationship	relationship	NN	_	4	nmod
8	between	between	IN	_	12	case
9	the	the	DT	_	12	det
10	functional	functional	JJ	_	12	amod
11	A118G	a118g	NN	_	12	compound
12	polymorphism	polymorphism	NN	_	7	nmod
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	OPRM1	oprm1	NN	_	16	compound
16	gene	gene	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	12	cc
21	drug2	drug2	NN	_	12	conj
22	in	in	IN	_	23	case
23	groups	group	NNS	_	21	nmod
24	of	of	IN	_	27	case
25	130	130	CD	_	27	nummod
26	male	male	NN	_	27	compound
27	patients	patient	NNS	_	23	nmod
28	and	and	CC	_	27	cc
29	452	452	CD	_	31	nummod
30	male	male	JJ	_	31	amod
31	controls	control	NNS	_	27	conj
32	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	7	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	present	present	JJ	_	6	amod
6	study	study	NN	_	2	nmod
7	reveal	reveal	VBP	_	0	ROOT
8	that	that	IN	_	14	mark
9	the	the	DT	_	12	det
10	drug1	drug1	NN	_	12	compound
11	gene	gene	NN	_	12	compound
12	polymorphism	polymorphism	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	associated	associate	VBN	_	7	ccomp
15	with	with	IN	_	19	case
16	a	a	DT	_	19	det
17	better	better	JJR	_	19	amod
18	glucose	glucose	NN	_	19	compound
19	tolerance	tolerance	NN	_	14	nmod
20	and	and	CC	_	7	cc
21	improved	improve	VBD	_	7	conj
22	IS	be	VBZ	_	21	dobj
23	,	,	,	_	22	punct
24	both	both	DT	_	27	nsubj
25	of	of	IN	_	26	case
26	which	which	WDT	_	24	nmod
27	suggest	suggest	VBP	_	22	ccomp
28	a	a	DT	_	31	det
29	potential	potential	JJ	_	31	amod
30	protective	protective	JJ	_	31	amod
31	effect	effect	NN	_	27	dobj
32	of	of	IN	_	34	case
33	this	this	DT	_	34	det
34	variant	variant	NN	_	31	nmod
35	on	on	IN	_	37	case
36	drug2	drug2	NN	_	37	compound
37	risk	risk	NN	_	31	nmod
38	.	.	.	_	7	punct
39	.	.	.	_	7	punct

1	Moreover	moreover	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	found	find	VBD	_	0	ROOT
5	that	that	IN	_	13	mark
6	the	the	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	allele	allele	NN	_	13	nsubj
9	was	be	VBD	_	13	cop
10	a	a	DT	_	13	det
11	dose-response	dose-response	JJ	_	13	amod
12	protective	protective	JJ	_	13	amod
13	factor	factor	NN	_	4	ccomp
14	for	for	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	the	the	DT	_	19	det
18	epsilon3	epsilon3	NN	_	19	compound
19	allele	allele	NN	_	20	nsubj
20	exerted	exert	VBD	_	13	conj
21	a	a	DT	_	25	det
22	weaker	weaker	JJR	_	25	amod
23	dose-response	dose-response	JJ	_	25	amod
24	protective	protective	JJ	_	25	amod
25	effect	effect	NN	_	20	dobj
26	for	for	IN	_	27	case
27	risk	risk	NN	_	25	nmod
28	of	of	IN	_	29	case
29	AD	ad	NN	_	27	nmod
30	compared	compare	VBN	_	32	case
31	with	with	IN	_	32	case
32	epsilon2	epsilon2	NN	_	20	advcl
33	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	was	be	VBD	_	5	auxpass
3	not	not	RB	_	5	neg
4	significantly	significantly	RB	_	5	advmod
5	associated	associate	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	10	case
9	our	we	PRP$	_	10	nmod:poss
10	sample	sample	NN	_	7	nmod
11	.	.	.	_	5	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Previous	previous	JJ	_	4	amod
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	investigated	investigate	VBN	_	1	dep
7	the	the	DT	_	8	det
8	role	role	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CTLA-4	ctla-4	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	and	and	CC	_	10	cc
15	drug2	drug2	NN	_	16	compound
16	factor-alpha	factor-alpha	NN	_	10	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	TNF-a	tnf-a	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	in	in	IN	_	21	case
21	carcinogenesis	carcinogenesis	NN	_	8	nmod
22	of	of	IN	_	23	case
23	osteosarcoma	osteosarcoma	NN	_	21	nmod
24	,	,	,	_	6	punct
25	but	but	CC	_	6	cc
26	their	they	PRP$	_	27	nmod:poss
27	results	result	NNS	_	29	nsubj
28	were	be	VBD	_	29	cop
29	inconsistent	inconsistent	JJ	_	6	conj
30	.	.	.	_	1	punct

1	Pooled	pool	VBN	_	2	amod
2	results	result	NNS	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	that	that	IN	_	10	mark
5	drug1	drug1	NN	_	6	compound
6	polymorphism	polymorphism	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	CTLA-4	ctla-4	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	associated	associate	VBN	_	3	ccomp
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	3	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	associations	association	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	found	find	VBN	_	0	ROOT
6	between	between	IN	_	8	case
7	drug1	drug1	CD	_	8	nummod
8	polymorphism	polymorphism	NN	_	5	nmod
9	of	of	IN	_	10	case
10	CTLA-4	ctla-4	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	drug2	drug2	NN	_	13	compound
13	polymorphism	polymorphism	NN	_	10	conj
14	of	of	IN	_	15	case
15	TNF-a	tnf-a	NN	_	10	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	18	compound
18	risk	risk	NN	_	15	conj
19	.	.	.	_	5	punct

1	The	the	DT	_	4	det
2	COMT	COMT	NNP	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	genotype	genotype	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	higher	higher	JJR	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	BIS-11	bis-11	NN	_	14	compound
13	second-order	second-order	NN	_	14	compound
14	factor	factor	NN	_	9	nmod
15	Non-planning	non-planning	JJ	_	14	amod
16	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	total	total	JJ	_	4	amod
4	population	population	NN	_	27	nmod
5	,	,	,	_	27	punct
6	inheritance	inheritance	NN	_	27	nsubj
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	IL1R2	il1r2	NN	_	11	compound
10	drug1	drug1	NN	_	11	compound
11	AA	aa	NN	_	6	nmod
12	,	,	,	_	6	punct
13	drug2	drug2	NN	_	14	compound
14	AA	aa	NN	_	6	conj
15	,	,	,	_	6	punct
16	TNF	tnf	NN	_	18	compound
17	drug3	drug3	NN	_	18	compound
18	GA	ga	NN	_	6	conj
19	+	+	CC	_	6	cc
20	AA	aa	NN	_	6	conj
21	,	,	,	_	6	punct
22	and	and	CC	_	6	cc
23	TNF	tnf	NN	_	25	compound
24	rs673	rs673	NN	_	25	compound
25	GA	ga	NN	_	6	conj
26	genotypesmodestly	genotypesmodestly	RB	_	27	advmod
27	increased	increase	VBD	_	0	ROOT
28	drug4	drug4	NN	_	29	compound
29	risk	risk	NN	_	27	dobj
30	by	by	IN	_	31	case
31	1.45	1.45	CD	_	27	nmod
32	to	to	TO	_	33	case
33	11.7-fold	11.7-fold	JJ	_	27	nmod
34	relative	relative	JJ	_	33	amod
35	to	to	TO	_	38	case
36	the	the	DT	_	38	det
37	referent	referent	JJ	_	38	amod
38	genotype	genotype	NN	_	34	nmod
39	.	.	.	_	27	punct

1	Among	among	IN	_	3	case
2	U.S.	U.S.	NNP	_	3	compound
3	men	man	NNS	_	19	nmod
4	,	,	,	_	19	punct
5	age-adjusted	age-adjusted	JJ	_	12	amod
6	dominant	dominant	JJ	_	12	amod
7	,	,	,	_	6	punct
8	recessive	recessive	JJ	_	6	conj
9	and	and	CC	_	6	cc
10	additive	additive	JJ	_	6	conj
11	genetic	genetic	JJ	_	12	amod
12	models	model	NNS	_	19	nsubjpass
13	for	for	IN	_	17	case
14	the	the	DT	_	17	det
15	IL1R2	il1r2	NN	_	17	compound
16	drug1	drug1	NN	_	17	compound
17	locus	locus	NN	_	12	nmod
18	were	be	VBD	_	19	auxpass
19	linked	link	VBN	_	0	ROOT
20	to	to	TO	_	22	case
21	an	a	DT	_	22	det
22	increase	increase	NN	_	19	nmod
23	in	in	IN	_	25	case
24	drug2	drug2	NN	_	25	compound
25	susceptibility	susceptibility	NN	_	22	nmod
26	.	.	.	_	19	punct

1	As	as	IN	_	4	case
2	for	for	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	polymorphism	polymorphism	NN	_	9	nmod
5	,	,	,	_	9	punct
6	the	the	DT	_	8	det
7	heterogeneous	heterogeneous	JJ	_	8	amod
8	genotype	genotype	NN	_	9	nsubj
9	showed	show	VBD	_	0	ROOT
10	a	a	DT	_	12	det
11	decreased	decrease	VBN	_	12	amod
12	risk	risk	NN	_	9	dobj
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	compared	compare	VBN	_	20	case
16	with	with	IN	_	20	case
17	the	the	DT	_	20	det
18	common	common	JJ	_	20	amod
19	homogenous	homogenous	JJ	_	20	amod
20	genotype	genotype	NN	_	12	nmod
21	in	in	IN	_	24	case
22	a	a	DT	_	24	det
23	fixed-effect	fixed-effect	JJ	_	24	amod
24	model	model	NN	_	20	nmod
25	in	in	IN	_	27	case
26	Asian	asian	JJ	_	27	amod
27	population	population	NN	_	24	nmod
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	Met/Val	met/val	JJ	_	30	amod
30	vs.	vs.	NN	_	20	dep

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	study	study	VB	_	0	ROOT
5	specific	specific	JJ	_	6	amod
6	features	feature	NNS	_	4	dobj
7	of	of	IN	_	8	mark
8	remitting	remit	VBG	_	6	acl
9	multiple	multiple	JJ	_	11	amod
10	sclerosis	sclerosis	NN	_	11	compound
11	patients	patient	NNS	_	8	dobj
12	with	with	IN	_	14	case
13	different	different	JJ	_	14	amod
14	genotypes	genotype	NNS	_	8	nmod
15	of	of	IN	_	20	case
16	polymorphic	polymorphic	JJ	_	20	amod
17	loci	locus	NNS	_	20	compound
18	rs1800629	rs1800629	NN	_	20	compound
19	gene	gene	NN	_	20	compound
20	TNFa	tnfa	NN	_	14	nmod
21	,	,	,	_	4	punct
22	drug1	drug1	NN	_	24	compound
23	gene	gene	NN	_	24	compound
24	CD40	cd40	NN	_	21	root
25	,	,	,	_	24	punct
26	drug2	drug2	NN	_	28	compound
27	gene	gene	NN	_	28	compound
28	KIF1B	kif1b	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug3	drug3	NN	_	32	compound
31	IL-18	il-18	NN	_	32	compound
32	gene	gene	NN	_	24	conj
33	,	,	,	_	24	punct
34	conducted	conduct	VBN	_	38	amod
35	clinical	clinical	JJ	_	38	amod
36	and	and	CC	_	35	cc
37	electrophysiological	electrophysiological	JJ	_	35	conj
38	examination	examination	NN	_	24	appos
39	of	of	IN	_	41	case
40	149	149	CD	_	41	nummod
41	patients	patient	NNS	_	38	nmod
42	with	with	IN	_	43	case
43	drug4	drug4	NN	_	41	nmod
44	.	.	.	_	24	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	determined	determine	VBN	_	0	ROOT
4	4	4	CD	_	8	nummod
5	frequent	frequent	JJ	_	8	amod
6	nonsynonymous	nonsynonymous	JJ	_	8	amod
7	gene	gene	NN	_	8	compound
8	polymorphisms	polymorphism	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	CYP1B1	cyp1b1	NN	_	8	nmod
11	in	in	IN	_	16	case
12	the	the	DT	_	16	det
13	human	human	JJ	_	16	amod
14	drug5	drug5	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	8	nmod
17	panels	panel	NNS	_	16	dep
18	of	of	IN	_	22	case
19	the	the	DT	_	22	det
20	National	National	NNP	_	22	compound
21	Cancer	Cancer	NNP	_	22	compound
22	Institut	Institut	NNP	_	17	nmod
23	e	e	SYM	_	22	dep
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	NCI	nci	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	and	and	CC	_	22	cc
28	the	the	DT	_	30	det
29	Japanese	japanese	JJ	_	30	amod
30	Foundation	Foundation	NNP	_	22	conj
31	for	for	IN	_	33	case
32	Cancer	Cancer	NNP	_	33	compound
33	Research	Research	NNP	_	30	nmod
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	JFCR	jfcr	NN	_	30	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	:	:	:	_	8	punct
38	drug1	drug1	NN	_	8	dep
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	R48G	r48g	NN	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	38	punct
43	drug2	drug2	NN	_	38	conj
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	A119S	a119s	NN	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	,	,	,	_	38	punct
48	drug3	drug3	NN	_	38	conj
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	L432V	l432v	NN	_	48	appos
51	-RRB-	-rrb-	-RRB-	_	50	punct
52	,	,	,	_	38	punct
53	and	and	CC	_	38	cc
54	drug4	drug4	NN	_	38	conj
55	-LRB-	-lrb-	-LRB-	_	56	punct
56	N453S	n453s	NN	_	54	appos
57	-RRB-	-rrb-	-RRB-	_	56	punct
58	.	.	.	_	3	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Evidence	evidence	NN	_	5	nsubj
4	has	have	VBZ	_	5	aux
5	suggested	suggest	VBN	_	1	dep
6	that	that	IN	_	5	dobj
7	tumour	tumour	NN	_	9	compound
8	necrosis	necrosis	NN	_	9	compound
9	factor	factor	NN	_	6	root
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	TNF	tnf	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	-	-	:	_	9	punct
14	a	a	DT	_	17	nsubjpass
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	involved	involve	VBN	_	9	acl:relcl
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	aetiology	aetiology	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	,	,	,	_	17	punct
24	but	but	CC	_	17	cc
25	the	the	DT	_	27	det
26	underlying	underlying	JJ	_	27	amod
27	association	association	NN	_	50	nsubj
28	of	of	IN	_	31	case
29	the	the	DT	_	31	det
30	TNF-a	tnf-a	NN	_	31	compound
31	polymorphisms	polymorphism	NNS	_	27	nmod
32	-238	-238	CD	_	33	nummod
33	G/A	g/a	NN	_	31	dep
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug1	drug1	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	and	and	CC	_	31	cc
38	-308	-308	CD	_	39	nummod
39	G/A	g/a	NN	_	31	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug2	drug2	NN	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	with	with	IN	_	45	case
44	the	the	DT	_	45	det
45	risk	risk	NN	_	27	nmod
46	of	of	IN	_	47	case
47	drug4	drug4	NN	_	45	nmod
48	is	be	VBZ	_	50	cop
49	still	still	RB	_	50	advmod
50	unconfirmed	unconfirmed	JJ	_	17	conj
51	.	.	.	_	9	punct

1	Evidence	evidence	NN	_	3	nsubj
2	has	have	VBZ	_	3	aux
3	suggested	suggest	VBN	_	0	ROOT
4	that	that	IN	_	3	dobj
5	tumour	tumour	NN	_	7	compound
6	necrosis	necrosis	NN	_	7	compound
7	factor	factor	NN	_	4	root
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	TNF	tnf	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	-	-	:	_	7	punct
12	a	a	DT	_	15	nsubjpass
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	involved	involve	VBN	_	7	dep
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	aetiology	aetiology	NN	_	15	nmod
19	of	of	IN	_	20	case
20	psoriasis	psoriasis	NN	_	18	nmod
21	,	,	,	_	15	punct
22	but	but	CC	_	15	cc
23	the	the	DT	_	25	det
24	underlying	underlying	JJ	_	25	amod
25	association	association	NN	_	44	nsubj
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	TNF-a	tnf-a	NN	_	29	compound
29	polymorphisms	polymorphism	NNS	_	25	nmod
30	-238	-238	CD	_	32	nummod
31	G/A	g/a	NN	_	32	compound
32	drug1	drug1	NN	_	29	dep
33	and	and	CC	_	32	cc
34	-308	-308	CD	_	36	nummod
35	G/A	g/a	NN	_	36	compound
36	drug2	drug2	NN	_	32	conj
37	with	with	IN	_	39	case
38	the	the	DT	_	39	det
39	risk	risk	NN	_	25	nmod
40	of	of	IN	_	41	case
41	drug3	drug3	NN	_	39	nmod
42	is	be	VBZ	_	44	cop
43	still	still	RB	_	44	advmod
44	<ModMar>	<modmar>	JJ	_	15	conj
45	unconfirmed	unconfirmed	JJ	_	46	amod
46	<ModMar>	<modmar>	NN	_	44	dobj

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	confirmed	confirm	VBN	_	1	appos
6	associations	association	NNS	_	5	dobj
7	between	between	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug1	drug1	NN	_	8	conj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	1	punct

1	Objective	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	We	we	PRP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	conducted	conduct	VBN	_	1	dep
6	the	the	DT	_	8	det
7	first	first	JJ	_	8	amod
8	study	study	NN	_	5	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	association	association	NN	_	8	nmod
12	of	of	IN	_	15	case
13	interleukin	interleukin	NN	_	15	compound
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	IL	il	NN	_	11	nmod
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	-10	-10	CD	_	15	nummod
18	,	,	,	_	15	punct
19	tumor	tumor	NN	_	22	compound
20	necrosis	necrosis	NN	_	22	compound
21	factor	factor	NN	_	22	compound
22	alpha	alpha	NN	_	15	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	TNF-a	tnf-a	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	15	punct
27	and	and	CC	_	15	cc
28	drug1	drug1	NN	_	29	compound
29	region	region	NN	_	32	compound
30	single	single	JJ	_	32	amod
31	nucleotide	nucleotide	NN	_	32	compound
32	polymorphisms	polymorphism	NNS	_	15	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	SNPs	snp	NNS	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	with	with	IN	_	37	case
37	drug2	drug2	NN	_	11	nmod
38	in	in	IN	_	40	case
39	Western	western	JJ	_	40	amod
40	Algeria	Algeria	NNP	_	37	nmod
41	.	.	.	_	1	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	show	show	VBP	_	0	ROOT
4	a	a	DT	_	6	det
5	potential	potential	JJ	_	6	amod
6	influence	influence	NN	_	3	dobj
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	drug1	drug1	NN	_	10	compound
10	deletion	deletion	NN	_	6	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	disease	disease	NN	_	13	nmod
17	among	among	IN	_	18	case
18	patients	patient	NNS	_	13	nmod
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	association	association	NN	_	2	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	combined	combined	JJ	_	12	amod
12	sample	sample	NN	_	2	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	n	n	NN	_	2	dep
15	=	=	JJ	_	14	amod
16	4071	4071	CD	_	15	dep
17	,	,	,	_	14	punct
18	p	p	NN	_	14	appos
19	=	=	JJ	_	18	amod
20	0.110	0.110	CD	_	19	dep
21	,	,	,	_	14	punct
22	odds	odds	NNS	_	23	compound
23	ratio	ratio	NN	_	14	appos
24	=	=	JJ	_	23	amod
25	1.08	1.08	CD	_	24	dep
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	.	.	.	_	2	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	5	nsubj
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	support	support	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	association	association	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	7	nmod
12	in	in	IN	_	16	case
13	the	the	DT	_	16	det
14	Han	Han	NNP	_	16	compound
15	Chinese	Chinese	NNP	_	16	compound
16	population	population	NN	_	11	nmod
17	.	.	.	_	5	punct

1	BACKGROUND	background	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Genotypes	genotype	NNS	_	23	nsubjpass
4	of	of	IN	_	8	case
5	tumor	tumor	NN	_	8	compound
6	necrosis	necrosis	NN	_	8	compound
7	factor	factor	NN	_	8	compound
8	alpha	alpha	NN	_	3	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	TNF-a	tnf-a	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	8	cc
13	its	its	PRP$	_	15	nmod:poss
14	surface	surface	NN	_	15	compound
15	receptors	receptor	NNS	_	8	conj
16	,	,	,	_	8	punct
17	drug1	drug1	NN	_	8	conj
18	and	and	CC	_	8	cc
19	drug2	drug2	NN	_	8	conj
20	,	,	,	_	3	punct
21	have	have	VBP	_	23	aux
22	been	be	VBN	_	23	auxpass
23	examined	examine	VBN	_	1	dep
24	in	in	IN	_	25	case
25	terms	term	NNS	_	23	nmod
26	of	of	IN	_	28	case
27	the	the	DT	_	28	det
28	progression	progression	NN	_	25	nmod
29	,	,	,	_	28	punct
30	metastasis	metastasis	NN	_	28	conj
31	,	,	,	_	28	punct
32	clinical	clinical	JJ	_	33	amod
33	efficacy	efficacy	NN	_	28	conj
34	,	,	,	_	28	punct
35	and	and	CC	_	28	cc
36	prognosis	prognosis	NN	_	28	conj
37	of	of	IN	_	39	case
38	various	various	JJ	_	39	amod
39	cancers	cancer	NNS	_	36	nmod
40	;	;	:	_	23	punct
41	however	however	RB	_	45	advmod
42	,	,	,	_	45	punct
43	little	little	JJ	_	45	nsubjpass
44	is	be	VBZ	_	45	auxpass
45	known	know	VBN	_	23	parataxis
46	about	about	IN	_	48	case
47	their	they	PRP$	_	48	nmod:poss
48	effects	effect	NNS	_	45	nmod
49	on	on	IN	_	51	case
50	clinical	clinical	JJ	_	51	amod
51	outcome	outcome	NN	_	48	nmod
52	in	in	IN	_	53	case
53	patients	patient	NNS	_	51	nmod
54	with	with	IN	_	55	case
55	drug3	drug3	NN	_	53	nmod
56	-LRB-	-lrb-	-LRB-	_	57	punct
57	ESCC	escc	NN	_	55	appos
58	-RRB-	-rrb-	-RRB-	_	57	punct
59	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	genotype	genotype	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	predictive	predictive	JJ	_	0	ROOT
5	of	of	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	response	response	NN	_	4	nmod
8	after	after	IN	_	9	case
9	treatment	treatment	NN	_	4	nmod
10	with	with	IN	_	13	case
11	definitive	definitive	JJ	_	13	amod
12	5-fluorouracil/cisplatin-based	5-fluorouracil/cisplatin-based	JJ	_	13	amod
13	chemoradiotherapy	chemoradiotherapy	NN	_	9	nmod
14	in	in	IN	_	16	case
15	Japanese	japanese	JJ	_	16	amod
16	patients	patient	NNS	_	13	nmod
17	with	with	IN	_	21	case
18	esophageal	esophageal	NN	_	21	compound
19	squamous	squamous	JJ	_	21	amod
20	cell	cell	NN	_	21	compound
21	drug2	drug2	NN	_	16	nmod
22	.	.	.	_	4	punct

1	Overall,TNF-a	overall,tnf-a	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	polymorphism	polymorphism	NN	_	6	nsubjpass
4	was	be	VBD	_	6	auxpass
5	significantly	significantly	RB	_	6	advmod
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	increased	increase	VBN	_	10	amod
10	risk	risk	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	under	under	IN	_	17	case
14	four	four	CD	_	17	nummod
15	genetic	genetic	JJ	_	17	amod
16	comparison	comparison	NN	_	17	compound
17	models	model	NNS	_	10	nmod

1	Remarkably	remarkably	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubj
4	was	be	VBD	_	7	cop
5	a	a	DT	_	7	det
6	protective	protective	JJ	_	7	amod
7	factor	factor	NN	_	0	ROOT
8	to	to	TO	_	9	mark
9	drug2	drug2	VB	_	7	acl
10	when	when	WRB	_	11	advmod
11	compared	compare	VBN	_	9	advcl
12	with	with	IN	_	13	case
13	BPH	BPH	NNP	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	OR	or	NN	_	13	appos
16	=	=	JJ	_	15	amod
17	0.550	0.550	CD	_	16	dep
18	;	;	:	_	15	punct
19	95	95	CD	_	20	compound
20	%	%	NN	_	21	amod
21	CI	ci	NN	_	15	dep
22	=	=	JJ	_	21	amod
23	0.311-0	0.311-0	CD	_	24	nummod
24	.975	.975	CD	_	22	dep
25	-RRB-	-rrb-	-RRB-	_	15	punct
26	,	,	,	_	7	punct
27	although	although	IN	_	33	mark
28	the	the	DT	_	31	det
29	statistically	statistically	RB	_	30	advmod
30	significant	significant	JJ	_	31	amod
31	difference	difference	NN	_	33	nsubjpass
32	was	be	VBD	_	33	auxpass
33	lost	lose	VBN	_	7	advcl
34	after	after	IN	_	35	case
35	correction	correction	NN	_	33	nmod
36	for	for	IN	_	38	case
37	multiple	multiple	JJ	_	38	amod
38	comparisons	comparison	NNS	_	35	nmod
39	.	.	.	_	7	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	associations	association	NNS	_	8	nsubjpass
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	variant	variant	NN	_	3	nmod
7	were	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	or	or	CC	_	10	cc
14	drug4	drug4	NN	_	16	compound
15	clinicopathologic	clinicopathologic	JJ	_	16	amod
16	status	status	NN	_	10	conj
17	.	.	.	_	8	punct

1	We	we	PRP	_	3	nsubj
2	have	have	VBP	_	3	aux
3	determined	determine	VBN	_	0	ROOT
4	4	4	CD	_	8	nummod
5	frequent	frequent	JJ	_	8	amod
6	nonsynonymous	nonsynonymous	JJ	_	8	amod
7	gene	gene	NN	_	8	compound
8	polymorphisms	polymorphism	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	CYP1B1	cyp1b1	NN	_	8	nmod
11	in	in	IN	_	16	case
12	the	the	DT	_	16	det
13	human	human	JJ	_	16	amod
14	tumor	tumor	NN	_	16	compound
15	cell	cell	NN	_	16	compound
16	lines	line	NNS	_	8	nmod
17	panels	panel	NNS	_	16	dep
18	of	of	IN	_	17	acl
19	the	the	DT	_	18	root
20	National	National	NNP	_	19	root
21	CancerInstitute	CancerInstitute	NNP	_	20	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	NCI	NCI	NNP	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	and	and	CC	_	21	cc
26	the	the	DT	_	28	det
27	Japanese	japanese	JJ	_	28	amod
28	Foundation	Foundation	NNP	_	21	conj
29	for	for	IN	_	31	case
30	drug5	drug5	NNP	_	31	compound
31	Research	Research	NNP	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	JFCR	jfcr	NN	_	28	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	:	:	:	_	20	punct
36	drug1	drug1	NN	_	20	dep
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	R48G	r48g	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	,	,	,	_	36	punct
41	drug2	drug2	NN	_	36	conj
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	A119S	a119s	NN	_	41	appos
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	,	,	,	_	36	punct
46	drug3	drug3	NN	_	36	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	L432V	l432v	NN	_	46	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	,	,	,	_	36	punct
51	and	and	CC	_	36	cc
52	drug4	drug4	NN	_	36	conj
53	-LRB-	-lrb-	-LRB-	_	54	punct
54	N453S	n453s	NN	_	52	appos
55	-RRB-	-rrb-	-RRB-	_	54	punct

1	Seven	seven	CD	_	3	nummod
2	polymorphic	polymorphic	JJ	_	3	amod
3	variants	variant	NNS	_	20	nsubjpass
4	in	in	IN	_	5	case
5	genes	gene	NNS	_	3	nmod
6	drug1	drug1	NN	_	5	dep
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug3	drug3	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug4	drug4	NN	_	6	conj
13	,	,	,	_	6	punct
14	drug5	drug5	NN	_	6	conj
15	,	,	,	_	6	punct
16	drug6	drug6	NN	_	6	conj
17	and	and	CC	_	6	cc
18	drug7	drug7	NN	_	6	conj
19	were	be	VBD	_	20	auxpass
20	associated	associate	VBN	_	0	ROOT
21	with	with	IN	_	22	case
22	drug8	drug8	NN	_	20	nmod
23	.	.	.	_	20	punct

1	Noteworthy	Noteworthy	NNP	_	13	nsubj
2	,	,	,	_	1	punct
3	the	the	DT	_	5	det
4	considerable	considerable	JJ	_	5	amod
5	number	number	NN	_	1	appos
6	of	of	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	carrying	carry	VBG	_	7	acl
9	drug1	drug1	NN	_	12	compound
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	alleles	allele	NNS	_	8	dobj
13	underlies	underlie	VBZ	_	0	ROOT
14	the	the	DT	_	15	det
15	importance	importance	NN	_	13	dobj
16	of	of	IN	_	17	mark
17	considering	consider	VBG	_	15	acl
18	pharmacogenetic	pharmacogenetic	JJ	_	19	amod
19	testing	testing	NN	_	17	dobj
20	before	before	IN	_	21	mark
21	starting	start	VBG	_	17	advcl
22	drug	drug	NN	_	24	compound
23	therapy	therapy	NN	_	24	compound
24	protocols	protocol	NNS	_	21	dobj
25	to	to	TO	_	26	mark
26	prevent	prevent	VB	_	21	advcl
27	toxicity	toxicity	NN	_	26	dobj
28	and/or	and/or	CC	_	27	cc
29	lack	lack	NN	_	27	conj
30	of	of	IN	_	31	case
31	effectiveness	effectiveness	NN	_	27	nmod
32	in	in	IN	_	33	case
33	drug3	drug3	NN	_	26	nmod
34	or	or	CC	_	33	cc
35	drug4	drug4	NN	_	37	compound
36	virus	virus	NN	_	37	compound
37	infections	infection	NNS	_	33	conj
38	.	.	.	_	13	punct

1	Logistic	logistic	JJ	_	3	amod
2	regression	regression	NN	_	3	compound
3	analysis	analysis	NN	_	4	nsubj
4	identified	identify	VBD	_	0	ROOT
5	two	two	CD	_	6	nummod
6	variants	variant	NNS	_	4	dobj
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	6	punct
11	the	the	DT	_	13	det
12	32-bp	32-bp	JJ	_	13	amod
13	deletion	deletion	NN	_	6	appos
14	within	within	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	the	the	DT	_	18	det
18	drug2	drug2	NN	_	13	conj
19	within	within	IN	_	22	case
20	the	the	DT	_	22	det
21	MTHFR	mthfr	NN	_	22	compound
22	gene	gene	NN	_	18	nmod
23	.	.	.	_	4	punct

1	Univariate	univariate	JJ	_	2	amod
2	analysis	analysis	NN	_	3	nsubj
3	detected	detect	VBD	_	0	ROOT
4	one	one	CD	_	7	nummod
5	significant	significant	JJ	_	7	amod
6	single-nucleotide	single-nucleotide	JJ	_	7	amod
7	polymorphism	polymorphism	NN	_	3	dobj
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	p	p	NN	_	10	nsubj
10	=	=	JJ	_	7	dep
11	0.03	0.03	CD	_	10	dobj
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	,	,	,	_	7	punct
14	drug1	drug1	NN	_	7	appos
15	,	,	,	_	7	punct
16	within	within	IN	_	19	case
17	the	the	DT	_	19	det
18	methylenetetrahydrofolate	methylenetetrahydrofolate	JJ	_	19	amod
19	reductase	reductase	NN	_	7	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	MTHFR	mthfr	NN	_	23	compound
22	-RRB-	-rrb-	-RRB-	_	23	punct
23	gene	gene	NN	_	19	dep
24	associated	associate	VBN	_	23	acl
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	23	punct

1	Logistic	logistic	JJ	_	3	amod
2	regression	regression	NN	_	3	compound
3	analysis	analysis	NN	_	4	nsubj
4	identified	identify	VBD	_	0	ROOT
5	two	two	CD	_	6	nummod
6	variants	variant	NNS	_	4	dobj
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	6	punct
11	the	the	DT	_	13	det
12	32-bp	32-bp	JJ	_	13	amod
13	deletion	deletion	NN	_	6	appos
14	within	within	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	the	the	DT	_	20	det
18	p.	p.	NN	_	20	compound
19	222A/V	222a/v	NN	_	20	compound
20	variant	variant	NN	_	15	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	within	within	IN	_	27	case
25	the	the	DT	_	27	det
26	MTHFR	mthfr	NN	_	27	compound
27	gene	gene	NN	_	13	nmod
28	.	.	.	_	4	punct

1	We	we	PRP	_	2	nsubj
2	explored	explore	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	influence	influence	NN	_	2	dobj
5	of	of	IN	_	6	case
6	interactions	interaction	NNS	_	4	nmod
7	between	between	IN	_	8	case
8	polymorphisms	polymorphism	NNS	_	6	nmod
9	acting	act	VBG	_	6	acl
10	upon	upon	IN	_	12	case
11	postsynaptic	postsynaptic	JJ	_	12	amod
12	receptors	receptor	NNS	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	DRD2	drd2	NN	_	16	compound
15	TaqA1	taqa1	NN	_	16	compound
16	drug1	drug1	NN	_	12	dep
17	and	and	CC	_	16	cc
18	DRD4	drd4	NN	_	19	compound
19	7R	7r	NN	_	16	conj
20	-RRB-	-rrb-	-RRB-	_	16	punct
21	and	and	CC	_	12	cc
22	dopamine	dopamine	NN	_	23	compound
23	regulators	regulator	NNS	_	12	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	COMT	comt	NN	_	26	compound
26	drug2	drug2	NN	_	23	dep
27	and	and	CC	_	26	cc
28	DAT1	dat1	NN	_	26	conj
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	on	on	IN	_	32	case
31	the	the	DT	_	32	det
32	expression	expression	NN	_	9	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	and	and	CC	_	34	cc
36	personality	personality	NN	_	34	conj
37	traits	trait	NNS	_	34	dep
38	in	in	IN	_	39	case
39	women	woman	NNS	_	32	nmod
40	with	with	IN	_	41	case
41	drug4	drug4	NN	_	39	nmod
42	.	.	.	_	2	punct

1	We	we	PRP	_	2	nsubj
2	observed	observe	VBD	_	0	ROOT
3	two	two	CD	_	5	nummod
4	epistatic	epistatic	JJ	_	5	amod
5	interactions	interaction	NNS	_	2	dobj
6	on	on	IN	_	8	case
7	symptom	symptom	NN	_	8	compound
8	indices	index	NNS	_	5	nmod
9	:	:	:	_	5	punct
10	interactions	interaction	NNS	_	19	nsubjpass
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	in	in	IN	_	14	case
13	predicted	predict	VBN	_	14	amod
14	directions	direction	NNS	_	10	nmod
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	10	nmod
18	were	be	VBD	_	19	auxpass
19	seen	see	VBN	_	5	dep
20	on	on	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	p	p	NN	_	24	nsubj
24	=	=	JJ	_	19	parataxis
25	.023	.023	CD	_	24	dobj
26	-RRB-	-rrb-	-RRB-	_	24	punct
27	,	,	,	_	19	punct
28	and	and	CC	_	19	cc
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	19	conj
31	on	on	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	p	p	NN	_	35	nsubj
35	=	=	JJ	_	30	dep
36	.014	.014	CD	_	35	dobj
37	-RRB-	-rrb-	-RRB-	_	35	punct
38	,	,	,	_	2	punct

1	STUDY	study	NN	_	2	compound
2	PURPOSES	purpose	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	,	,	,	_	2	punct
5	Analysis	analysis	NN	_	2	appos
6	of	of	IN	_	7	case
7	influence	influence	NN	_	5	nmod
8	of	of	IN	_	11	case
9	allelic	allelic	JJ	_	11	amod
10	polymorphisms	polymorphism	NNS	_	11	compound
11	C1444T	c1444t	NN	_	7	nmod
12	of	of	IN	_	15	case
13	CRP	crp	NN	_	15	compound
14	gene	gene	NN	_	15	compound
15	drug1	drug1	NN	_	11	nmod
16	,	,	,	_	15	punct
17	G	g	NN	_	21	compound
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	-174	-174	CD	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	A	a	DT	_	15	appos
22	of	of	IN	_	25	case
23	IL6	il6	NN	_	25	compound
24	gene	gene	NN	_	25	compound
25	drug2	drug2	NN	_	21	nmod
26	,	,	,	_	25	punct
27	A	a	NN	_	31	compound
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	-308	-308	CD	_	31	nummod
30	-RRB-	-rrb-	-RRB-	_	31	punct
31	G	g	NN	_	25	appos
32	of	of	IN	_	35	case
33	TNF	tnf	NN	_	35	compound
34	gene	gene	NN	_	35	compound
35	drug3	drug3	NN	_	31	nmod
36	,	,	,	_	25	punct
37	G252A	g252a	NN	_	25	appos
38	of	of	IN	_	41	case
39	LTA	lta	NN	_	41	compound
40	gene	gene	NN	_	41	compound
41	drug4	drug4	NN	_	37	nmod
42	,	,	,	_	25	punct
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	-509	-509	CD	_	25	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	of	of	IN	_	49	case
47	TGFB1	tgfb1	NN	_	49	compound
48	gene	gene	NN	_	49	compound
49	drug5	drug5	NN	_	25	nmod
50	and	and	CC	_	49	cc
51	delta32	delta32	NN	_	49	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	w/d	w/d	NN	_	51	appos
54	-RRB-	-rrb-	-RRB-	_	53	punct
55	of	of	IN	_	58	case
56	CCR5	ccr5	NN	_	58	compound
57	gene	gene	NN	_	58	compound
58	drug6	drug6	NN	_	49	nmod
59	on	on	IN	_	60	case
60	development	development	NN	_	21	nmod
61	of	of	IN	_	62	case
62	drug7	drug7	NN	_	60	nmod
63	in	in	IN	_	65	case
64	Russian	russian	JJ	_	65	amod
65	patients	patient	NNS	_	60	nmod
66	with	with	IN	_	67	case
67	MI	mi	NN	_	65	nmod
68	during	during	IN	_	70	case
69	two	two	CD	_	70	nummod
70	years	year	NNS	_	21	nmod
71	follow-up	follow-up	JJ	_	70	amod

1	Methods	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	total	total	NN	_	19	nsubjpass
5	of	of	IN	_	8	case
6	51	51	CD	_	8	nummod
7	drug12	drug12	NN	_	8	compound
8	patients	patient	NNS	_	4	nmod
9	and	and	CC	_	8	cc
10	96	96	CD	_	12	nummod
11	unrelated	unrelated	JJ	_	12	amod
12	controls	control	NNS	_	8	conj
13	from	from	IN	_	15	case
14	West	West	NNP	_	15	compound
15	region	region	NN	_	4	nmod
16	of	of	IN	_	17	case
17	Algeria	Algeria	NNP	_	15	nmod
18	were	be	VBD	_	19	auxpass
19	genotyped	genotype	VBN	_	1	appos
20	by	by	IN	_	22	case
21	direct	direct	JJ	_	22	amod
22	sequencing	sequencing	NN	_	19	nmod
23	for	for	IN	_	25	case
24	11	11	CD	_	25	nummod
25	SNPs	snp	NNS	_	19	nmod
26	including	include	VBG	_	28	case
27	2	2	CD	_	28	nummod
28	SNPs	snp	NNS	_	25	nmod
29	from	from	IN	_	32	case
30	the	the	DT	_	32	det
31	IL10	il10	NN	_	32	compound
32	promoter	promoter	NN	_	28	nmod
33	-LSB-	-lsb-	-LRB-	_	37	punct
34	c.-819T	c.-819t	NN	_	37	compound
35	>	>	JJR	_	37	amod
36	C	c	NN	_	37	compound
37	drug1	drug1	NN	_	28	dep
38	,	,	,	_	37	punct
39	c.-592A	c.-592a	NN	_	42	compound
40	>	>	JJR	_	42	amod
41	C	c	NN	_	42	compound
42	drug2	drug2	NN	_	37	conj
43	,	,	,	_	37	punct
44	6	6	CD	_	45	nummod
45	SNPs	snp	NNS	_	37	conj
46	from	from	IN	_	49	case
47	the	the	DT	_	49	det
48	TNF-a	tnf-a	NN	_	49	compound
49	promoter	promoter	NN	_	45	nmod
50	-LSB-	-lsb-	-LRB-	_	54	punct
51	c.-1211T	c.-1211t	NN	_	54	compound
52	>	>	JJR	_	54	amod
53	C	c	NN	_	54	compound
54	drug3	drug3	NN	_	45	dep
55	,	,	,	_	54	punct
56	c.-1043C	c.-1043c	NN	_	57	compound
57	drug4	drug4	NN	_	54	conj
58	,	,	,	_	54	punct
59	c.-1037C	c.-1037c	NN	_	62	compound
60	>	>	JJR	_	62	amod
61	T	t	NN	_	62	compound
62	drug5	drug5	NN	_	54	conj
63	,	,	,	_	54	punct
64	c.-556G	c.-556g	NN	_	67	compound
65	>	>	JJR	_	67	advmod
66	A	a	DT	_	67	det
67	drug6	drug6	NN	_	54	conj
68	,	,	,	_	54	punct
69	c.-488G	c.-488g	NN	_	72	compound
70	>	>	JJR	_	72	advmod
71	A	a	DT	_	72	det
72	drug7	drug7	NN	_	54	conj
73	,	,	,	_	54	punct
74	and	and	CC	_	54	cc
75	c.-418G	c.-418g	NN	_	78	dep
76	>	>	JJR	_	78	advmod
77	A	a	DT	_	78	det
78	drug8	drug8	NN	_	54	conj
79	-RSB-	-rsb-	-RRB-	_	54	punct
80	,	,	,	_	37	punct
81	and	and	CC	_	37	cc
82	3	3	CD	_	83	nummod
83	SNPs	snp	NNS	_	37	conj
84	from	from	IN	_	87	case
85	the	the	DT	_	87	det
86	IL23R-IL12RB2	il23r-il12rb2	NN	_	87	compound
87	region	region	NN	_	83	nmod
88	-LSB-	-lsb-	-LRB-	_	93	punct
89	g.	g.	NN	_	93	compound
90	67747415A	67747415a	NN	_	93	compound
91	>	>	JJR	_	93	amod
92	C	c	NN	_	93	compound
93	drug9	drug9	NN	_	37	dep
94	,	,	,	_	93	punct
95	g.	g.	NN	_	96	compound
96	67740092G	67740092g	NN	_	93	conj
97	>	>	JJR	_	99	advmod
98	A	a	DT	_	99	det
99	drug10	drug10	NN	_	96	dep
100	,	,	,	_	93	punct
101	and	and	CC	_	93	cc
102	g.	g.	NN	_	106	compound
103	67760140T	67760140t	CD	_	106	nummod
104	>	>	JJR	_	106	advmod
105	C	c	NN	_	106	compound
106	drug11	drug11	NN	_	93	conj
107	-RSB-	-rsb-	-RRB-	_	93	punct
108	.	.	.	_	1	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	VARIOUS	various	JJ	_	4	amod
4	SNPS	snp	NNS	_	5	nsubj
5	REACHED	reach	VBD	_	1	appos
6	NOMINAL	nominal	JJ	_	7	amod
7	SIGNIFICANCE	SIGNIFICANCE	NNP	_	5	dobj
8	:	:	:	_	7	punct
9	drug12	drug12	NN	_	7	dep
10	and	and	CC	_	9	cc
11	drug13	drug13	NN	_	9	conj
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	9	punct
17	drug14	drug14	NN	_	9	appos
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	,	,	,	_	9	punct
21	drug15	drug15	NN	_	9	appos
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	,	,	,	_	9	punct
25	drug16	drug16	NN	_	9	appos
26	with	with	IN	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	and	and	CC	_	27	cc
29	drug6	drug6	NN	_	27	conj
30	,	,	,	_	9	punct
31	drug17	drug17	NN	_	9	appos
32	with	with	IN	_	33	case
33	drug7	drug7	NN	_	31	nmod
34	,	,	,	_	9	punct
35	drug18	drug18	NN	_	9	appos
36	with	with	IN	_	37	case
37	drug8	drug8	NN	_	35	nmod
38	,	,	,	_	9	punct
39	drug19	drug19	NN	_	9	appos
40	with	with	IN	_	41	case
41	drug9	drug9	NN	_	39	nmod
42	,	,	,	_	41	punct
43	drug10	drug10	NN	_	41	conj
44	and	and	CC	_	41	cc
45	drug11	drug11	NN	_	41	conj
46	.	.	.	_	1	punct

1	We	we	PRP	_	2	nsubj
2	found	find	VBD	_	0	ROOT
3	a	a	DT	_	6	det
4	significant	significant	JJ	_	6	amod
5	genotype	genotype	NN	_	6	compound
6	effect	effect	NN	_	2	dobj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	all	all	DT	_	9	det
9	P	p	NN	_	10	nsubj
10	<	<	VBG	_	6	dep
11	0.017	0.017	CD	_	10	dobj
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	for	for	IN	_	17	case
14	the	the	DT	_	17	det
15	following	follow	VBG	_	17	amod
16	smoking-related	smoking-related	JJ	_	17	amod
17	phenotypes	phenotype	NNS	_	6	nmod
18	:	:	:	_	2	punct
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	i	i	LS	_	23	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	cigarettes	cigarette	NNS	_	23	nsubj
23	smoked	smoke	VBD	_	2	dep
24	per	per	IN	_	25	case
25	day	day	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	CYP2A13	cyp2a13	NN	_	29	dep
28	*	*	SYM	_	29	dep
29	3	3	CD	_	23	conj
30	;	;	:	_	23	punct
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	ii	ii	LS	_	36	dep
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	pack	pack	NN	_	35	compound
35	years	year	NNS	_	36	nsubj
36	smoked	smoke	VBN	_	23	parataxis
37	and	and	CC	_	36	cc
38	CYP2A6	cyp2a6	NN	_	40	dep
39	*	*	SYM	_	40	dep
40	2	2	CD	_	36	conj
41	,	,	,	_	36	punct
42	CYP2A6	cyp2a6	NN	_	36	dep
43	*	*	SYM	_	46	dep
44	1	1	CD	_	46	compound
45	*	*	SYM	_	46	dep
46	2	2	CD	_	42	dep
47	,	,	,	_	46	punct
48	drug1	drug1	NN	_	46	appos
49	,	,	,	_	46	punct
50	CYP2B6	cyp2b6	NN	_	52	dep
51	*	*	SYM	_	52	dep
52	4	4	CD	_	46	conj
53	and	and	CC	_	52	cc
54	DRD2-ANKK1	drd2-ankk1	NN	_	52	conj
55	2137G	2137g	NN	_	52	dep
56	>	>	JJR	_	55	advmod
57	A	a	NN	_	56	dep
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	Taq1A	taq1a	NN	_	57	appos
60	-RRB-	-rrb-	-RRB-	_	59	punct
61	;	;	:	_	46	punct
62	-LRB-	-lrb-	-LRB-	_	63	punct
63	iii	iii	LS	_	65	dep
64	-RRB-	-rrb-	-RRB-	_	63	punct
65	drug3	drug3	NN	_	46	dep
66	-LRB-	-lrb-	-LRB-	_	67	punct
67	assessed	assess	VBN	_	65	dep
68	with	with	IN	_	71	case
69	the	the	DT	_	71	det
70	Fagestrom	Fagestrom	NNP	_	71	compound
71	test	test	NN	_	67	nmod
72	-RRB-	-rrb-	-RRB-	_	67	punct
73	and	and	CC	_	65	cc
74	drug2	drug2	NN	_	65	conj
75	.	.	.	_	2	punct

1	The	the	DT	_	5	det
2	best-studied	best-studied	JJ	_	5	amod
3	functional	functional	JJ	_	5	amod
4	genetic	genetic	JJ	_	5	amod
5	variant	variant	JJ	_	11	nsubj
6	relevant	relevant	JJ	_	5	amod
7	to	to	TO	_	9	case
8	drug2	drug2	NN	_	9	compound
9	treatment	treatment	NN	_	6	nmod
10	is	be	VBZ	_	11	cop
11	drug1	drug1	NN	_	0	ROOT
12	,	,	,	_	11	punct
13	a	a	DT	_	15	det
14	single-nucleotide	single-nucleotide	JJ	_	15	amod
15	polymorphism	polymorphism	NN	_	11	appos
16	in	in	IN	_	17	case
17	exon	exon	NN	_	15	nmod
18	1	1	CD	_	17	nummod
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	OPRM1	oprm1	NN	_	22	compound
22	gene	gene	NN	_	17	nmod
23	that	that	WDT	_	24	nsubj
24	encodes	encode	VBZ	_	22	acl:relcl
25	the	the	DT	_	27	det
26	u-opioid	u-opioid	JJ	_	27	amod
27	receptor	receptor	NN	_	24	dobj
28	.	.	.	_	11	punct

1	METHODS	method	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	association	association	NN	_	21	nsubjpass
5	between	between	IN	_	8	case
6	the	the	DT	_	8	det
7	OPRM1	oprm1	NN	_	8	compound
8	A118G	a118g	NN	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	Asn40Asp	asn40asp	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	polymorphism	polymorphism	NN	_	8	dep
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	and	and	CC	_	8	cc
18	alcohol	alcohol	NN	_	19	compound
19	consumption	consumption	NN	_	8	conj
20	was	be	VBD	_	21	auxpass
21	analyzed	analyze	VBN	_	1	dep
22	using	use	VBG	_	21	xcomp
23	three	three	CD	_	26	nummod
24	different	different	JJ	_	26	amod
25	population-based	population-based	JJ	_	26	amod
26	samples	sample	NNS	_	22	dobj
27	:	:	:	_	21	punct
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	a	a	LS	_	21	parataxis
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	a	a	DT	_	34	det
32	Finnish	finnish	JJ	_	34	amod
33	cohort	cohort	NN	_	34	compound
34	study	study	NN	_	29	dep
35	,	,	,	_	34	punct
36	Health	Health	NNP	_	34	appos
37	2000	2000	CD	_	36	nummod
38	,	,	,	_	34	punct
39	with	with	IN	_	41	case
40	503	503	CD	_	41	nummod
41	participants	participant	NNS	_	34	nmod
42	having	have	VBG	_	41	acl
43	a	a	DT	_	45	det
44	DSM-IV	dsm-iv	NN	_	45	compound
45	diagnosis	diagnosis	NN	_	42	dobj
46	for	for	IN	_	47	case
47	drug3	drug3	NN	_	45	nmod
48	and/or	and/or	CC	_	47	cc
49	drug4	drug4	NN	_	47	conj
50	and	and	CC	_	47	cc
51	506	506	CD	_	52	nummod
52	age	age	NN	_	47	conj
53	-	-	:	_	34	punct
54	and	and	CC	_	34	cc
55	sex-matched	sex-matched	JJ	_	56	amod
56	controls	control	NNS	_	34	conj
57	;	;	:	_	34	punct
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	b	b	LS	_	64	dep
60	-RRB-	-rrb-	-RRB-	_	59	punct
61	a	a	DT	_	64	det
62	Finnish	finnish	JJ	_	64	amod
63	cohort	cohort	NN	_	64	compound
64	study	study	NN	_	34	dep
65	,	,	,	_	64	punct
66	FINRISK	finrisk	NN	_	64	conj
67	-LRB-	-lrb-	-LRB-	_	68	punct
68	n	n	NN	_	66	dep
69	=	=	JJ	_	68	amod
70	2360	2360	CD	_	69	dep
71	-RRB-	-rrb-	-RRB-	_	68	punct
72	and	and	CC	_	64	cc
73	-LRB-	-lrb-	-LRB-	_	74	punct
74	c	c	LS	_	64	conj
75	-RRB-	-rrb-	-RRB-	_	74	punct
76	the	the	DT	_	80	det
77	Helsinki	Helsinki	NNP	_	80	compound
78	Birth	Birth	NNP	_	80	compound
79	Cohort	Cohort	NNP	_	80	compound
80	Study	Study	NNP	_	74	dobj
81	-LRB-	-lrb-	-LRB-	_	82	punct
82	n	n	NN	_	80	dep
83	=	=	JJ	_	82	amod
84	1384	1384	CD	_	83	dep
85	-RRB-	-rrb-	-RRB-	_	82	punct
86	.	.	.	_	29	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	case-control	case-control	JJ	_	4	amod
4	study	study	NN	_	36	nmod
5	that	that	WDT	_	6	nsubj
6	included	include	VBD	_	4	acl:relcl
7	187patients	187patient	NNS	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	cases	case	NNS	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	and	and	CC	_	9	cc
14	189	189	CD	_	16	nummod
15	normal	normal	JJ	_	16	amod
16	subjects	subject	NNS	_	9	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	controls	control	NNS	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	36	punct
21	the	the	DT	_	23	det
22	AA	AA	NNP	_	23	compound
23	genotype	genotype	NN	_	36	nsubj
24	and	and	CC	_	23	cc
25	variant	variant	JJ	_	28	amod
26	Met	Met	NNP	_	28	compound
27	allele	allele	NN	_	28	compound
28	frequencies	frequency	NNS	_	23	conj
29	of	of	IN	_	30	case
30	drug1	drug1	NN	_	23	nmod
31	in	in	IN	_	33	case
32	the	the	DT	_	33	det
33	COMTgene	comtgene	NN	_	30	nmod
34	were	be	VBD	_	36	cop
35	significantly	significantly	RB	_	36	advmod
36	higher	higher	JJR	_	0	ROOT
37	in	in	IN	_	38	case
38	patients	patient	NNS	_	36	nmod
39	with	with	IN	_	40	case
40	drug3	drug3	NN	_	38	nmod
41	than	than	IN	_	42	case
42	those	those	DT	_	36	nmod
43	in	in	IN	_	46	case
44	the	the	DT	_	46	det
45	control	control	NN	_	46	compound
46	group	group	NN	_	42	nmod
47	-LRB-	-lrb-	-LRB-	_	50	punct
48	both	both	DT	_	50	dep
49	p	p	NN	_	50	dep
50	<	<	JJR	_	42	dep
51	0.05	0.05	CD	_	50	nummod
52	-RRB-	-rrb-	-RRB-	_	50	punct
53	.	.	.	_	36	punct

1	Compared	compare	VBN	_	3	case
2	with	with	IN	_	3	case
3	nonsmokers	nonsmoker	NNS	_	13	nmod
4	,	,	,	_	13	punct
5	European-American	European-American	NNP	_	9	compound
6	COMT	COMT	NNP	_	9	compound
7	drug1	drug1	NN	_	9	compound
8	double-variant	double-variant	JJ	_	9	amod
9	carriers	carrier	NNS	_	13	nsubj
10	who	who	WP	_	11	nsubj
11	smoked	smoke	VBD	_	9	acl:relcl
12	had	have	VBD	_	13	aux
13	increased	increase	VBN	_	0	ROOT
14	odds	odds	NNS	_	13	dobj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	-LSB-	-lsb-	-LRB-	_	20	punct
18	adjusted	adjust	VBN	_	20	amod
19	odds	odds	NNS	_	20	compound
20	ratio	ratio	NN	_	13	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	AOR	aor	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	6.15	6.15	CD	_	20	nummod
25	,	,	,	_	20	punct
26	95	95	CD	_	27	compound
27	%	%	NN	_	29	amod
28	confidence	confidence	NN	_	29	compound
29	interval	interval	NN	_	20	appos
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	CI	ci	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	1.32-28	1.32-28	CD	_	34	nummod
34	.78	.78	CD	_	29	dep
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	-RSB-	-rsb-	-RRB-	_	20	punct
37	;	;	:	_	13	punct

1	European-American	European-American	NNP	_	5	compound
2	COMT	COMT	NNP	_	5	compound
3	drug1	drug1	NN	_	5	compound
4	double-variant	double-variant	JJ	_	5	amod
5	carriers	carrier	NNS	_	0	ROOT
6	who	who	WP	_	7	nsubj
7	smoked	smoke	VBD	_	5	acl:relcl
8	heavily	heavily	RB	_	7	advmod
9	had	have	VBN	_	7	dep
10	more	more	RBR	_	11	advmod
11	frequent	frequent	JJ	_	15	amod
12	moderate	moderate	JJ	_	15	amod
13	or	or	CC	_	12	cc
14	severe	severe	JJ	_	12	conj
15	drug2	drug2	NN	_	9	dobj
16	than	than	IN	_	17	case
17	nonsmokers	nonsmoker	NNS	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	AOR	aor	NN	_	17	dep
20	13.7	13.7	CD	_	19	nummod
21	,	,	,	_	19	punct
22	95	95	CD	_	23	compound
23	%	%	NN	_	24	amod
24	CI	ci	NN	_	19	appos
25	1.2-154	1.2-154	CD	_	26	nummod
26	.9	.9	CD	_	24	nummod
27	-RRB-	-rrb-	-RRB-	_	19	punct
28	.	.	.	_	5	punct

1	European-American	European-American	NNP	_	4	compound
2	drug1	drug1	NN	_	4	compound
3	double-variant	double-variant	JJ	_	4	amod
4	carriers	carrier	NNS	_	0	ROOT
5	who	who	WP	_	6	nsubj
6	smoked	smoke	VBD	_	4	acl:relcl
7	described	describe	VBN	_	6	xcomp
8	more	more	RBR	_	9	advmod
9	frequent	frequent	JJ	_	13	amod
10	moderate	moderate	JJ	_	13	amod
11	or	or	CC	_	10	cc
12	severe	severe	JJ	_	10	conj
13	drug2	drug2	NN	_	7	dobj
14	than	than	IN	_	15	case
15	nonsmoking	nonsmoking	JJ	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	AOR	aor	NN	_	15	dep
18	20.6	20.6	CD	_	17	nummod
19	,	,	,	_	17	punct
20	95	95	CD	_	21	compound
21	%	%	NN	_	22	amod
22	CI	ci	NN	_	17	appos
23	1.64-257	1.64-257	CD	_	24	compound
24	.93	.93	CD	_	22	nummod
25	-RRB-	-rrb-	-RRB-	_	17	punct
26	and	and	CC	_	15	cc
27	never-smoking	never-smoking	NN	_	15	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	AOR	aor	NN	_	27	dep
30	20.59	20.59	CD	_	29	nummod
31	,	,	,	_	29	punct
32	95	95	CD	_	33	compound
33	%	%	NN	_	34	amod
34	CI	ci	NN	_	29	appos
35	1.39-304	1.39-304	CD	_	36	compound
36	.68	.68	CD	_	34	nummod
37	-RRB-	-rrb-	-RRB-	_	29	punct
38	carriers	carrier	NNS	_	15	dep
39	,	,	,	_	7	punct
40	respectively	respectively	RB	_	7	advmod
41	.	.	.	_	4	punct

1	African-American	african-american	JJ	_	4	amod
2	single-variant	single-variant	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	carriers	carrier	NNS	_	9	nsubj
5	who	who	WP	_	6	nsubj
6	smoked	smoke	VBN	_	4	acl:relcl
7	were	be	VBD	_	9	cop
8	more	more	RBR	_	9	advmod
9	likely	likely	JJ	_	0	ROOT
10	to	to	TO	_	11	mark
11	report	report	VB	_	9	xcomp
12	drug2	drug2	NN	_	11	dobj
13	than	than	IN	_	16	case
14	the	the	DT	_	16	det
15	nonsmoking	nonsmoking	JJ	_	16	amod
16	carriers	carrier	NNS	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	AOR	aor	NN	_	16	dep
19	6.16	6.16	CD	_	18	nummod
20	,	,	,	_	18	punct
21	95	95	CD	_	22	compound
22	%	%	NN	_	23	amod
23	CI	ci	NN	_	18	appos
24	1.11-33	1.11-33	CD	_	25	nummod
25	.91	.91	CD	_	23	nummod
26	-RRB-	-rrb-	-RRB-	_	18	punct
27	.	.	.	_	9	punct

1	This	this	DT	_	2	det
2	study	study	NN	_	0	ROOT
3	aimed	aim	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	test	test	VB	_	3	xcomp
6	the	the	DT	_	7	det
7	association	association	NN	_	5	dobj
8	between	between	IN	_	12	case
9	the	the	DT	_	12	det
10	Val158Met	val158met	NN	_	12	compound
11	polymorphism	polymorphism	NN	_	12	compound
12	drug1	drug1	NN	_	7	nmod
13	of	of	IN	_	20	case
14	the	the	DT	_	20	det
15	catechol-O-methyl	catechol-o-methyl	NN	_	20	compound
16	transferase	transferase	NN	_	20	compound
17	gene	gene	NN	_	20	compound
18	andanorexia	andanorexia	NN	_	20	compound
19	nervosa	nervosa	NN	_	20	compound
20	drug2	drug2	NN	_	12	nmod
21	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	present	present	JJ	_	4	amod
3	association	association	NN	_	4	compound
4	studies	study	NNS	_	5	nsubj
5	found	find	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	association	association	NN	_	5	dobj
8	between	between	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug1	drug1	NN	_	9	conj
12	when	when	WRB	_	13	advmod
13	testing	test	VBG	_	5	advcl
14	the	the	DT	_	16	det
15	allelic	allelic	JJ	_	16	amod
16	contrast	contrast	NN	_	13	dobj
17	-LSB-	-lsb-	-LRB-	_	20	punct
18	Utrecht	Utrecht	NNP	_	20	compound
19	odds	odds	NNS	_	20	compound
20	ratio	ratio	NN	_	16	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	OR	or	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	=	=	JJ	_	20	amod
25	1.14	1.14	CD	_	24	dep
26	,	,	,	_	20	punct
27	P	p	NN	_	20	appos
28	=	=	JJ	_	27	amod
29	0.14	0.14	CD	_	28	dep
30	;	;	:	_	20	punct
31	Leiden	Leiden	NNP	_	32	compound
32	OR	or	NN	_	20	dep
33	=	=	JJ	_	32	amod
34	1.02	1.02	CD	_	33	dep
35	,	,	,	_	32	punct
36	P	p	NN	_	37	nsubj
37	=	=	JJ	_	32	dep
38	0.85	0.85	CD	_	37	dobj
39	-RSB-	-rsb-	-RRB-	_	20	punct
40	.	.	.	_	5	punct

1	Meta-analytically	meta-analytically	RB	_	2	advmod
2	combined	combine	VBN	_	3	amod
3	evidence	evidence	NN	_	12	nsubj
4	from	from	IN	_	7	case
5	the	the	DT	_	7	det
6	present	present	JJ	_	7	amod
7	genotypings	genotyping	NNS	_	3	nmod
8	and	and	CC	_	7	cc
9	the	the	DT	_	11	det
10	literature	literature	NN	_	11	compound
11	search	search	NN	_	7	conj
12	shows	show	VBZ	_	0	ROOT
13	that	that	IN	_	18	mark
14	the	the	DT	_	16	det
15	effect	effect	NN	_	16	compound
16	sizes	size	NNS	_	18	nsubj
17	are	be	VBP	_	18	cop
18	homogeneous	homogeneous	JJ	_	12	ccomp
19	across	across	IN	_	20	case
20	studies	study	NNS	_	18	nmod
21	and	and	CC	_	18	cc
22	that	that	IN	_	26	mark
23	drug1	drug1	NN	_	26	nsubjpass
24	is	be	VBZ	_	26	auxpass
25	not	not	RB	_	26	neg
26	associated	associate	VBN	_	18	conj
27	with	with	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	12	punct

1	the	the	DT	_	4	det
2	COMT	COMT	NNP	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	SNP	snp	NN	_	13	nsubjpass
5	that	that	WDT	_	6	nsubj
6	reduces	reduce	VBZ	_	4	acl:relcl
7	enzyme	enzyme	NN	_	8	compound
8	activity	activity	NN	_	6	dobj
9	,	,	,	_	4	punct
10	has	have	VBZ	_	13	aux
11	previously	previously	RB	_	13	advmod
12	been	be	VBN	_	13	auxpass
13	linked	link	VBN	_	0	ROOT
14	to	to	TO	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	13	punct

1	Although	although	IN	_	9	mark
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	SNP	snp	NN	_	9	nsubj
5	was	be	VBD	_	9	cop
6	not	not	RB	_	9	neg
7	a	a	DT	_	9	det
8	risk	risk	NN	_	9	compound
9	factor	factor	NN	_	0	ROOT
10	for	for	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	9	punct

1	We	we	PRP	_	2	nsubj
2	conclude	conclude	VBP	_	0	ROOT
3	that	that	IN	_	9	mark
4	the	the	DT	_	8	det
5	functional	functional	JJ	_	8	amod
6	COMT	COMT	NNP	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	SNP	snp	NN	_	9	nsubj
9	contributes	contribute	VBZ	_	2	ccomp
10	to	to	TO	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	and	and	CC	_	11	cc
15	drug4	drug4	NN	_	11	conj
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	authors	author	NNS	_	3	nsubj
3	examined	examine	VBN	_	0	ROOT
4	relations	relation	NNS	_	3	dobj
5	between	between	IN	_	7	case
6	reproductive	reproductive	JJ	_	7	amod
7	factors	factor	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	5	5	CD	_	13	nummod
10	estrogen	estrogen	NN	_	13	compound
11	pathway	pathway	NN	_	13	compound
12	gene	gene	NN	_	13	compound
13	polymorphisms	polymorphism	NNS	_	7	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug1	drug1	NN	_	13	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug3	drug3	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug4	drug4	NN	_	15	conj
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	COMT	COMT	NNP	_	25	compound
25	drug5	drug5	NN	_	15	conj
26	-RRB-	-rrb-	-RRB-	_	15	punct
27	among	among	IN	_	33	case
28	702	702	CD	_	33	nummod
29	Singapore	Singapore	NNP	_	33	compound
30	Chinese	Chinese	NNP	_	33	compound
31	female	female	JJ	_	33	amod
32	drug6	drug6	NN	_	33	compound
33	cases	case	NNS	_	4	nmod
34	and	and	CC	_	33	cc
35	1,578	1,578	CD	_	37	nummod
36	hospital	hospital	NN	_	37	compound
37	controls	control	NNS	_	33	conj
38	,	,	,	_	33	punct
39	of	of	IN	_	40	case
40	whom	whom	WP	_	56	nmod
41	433	433	CD	_	42	nummod
42	cases	case	NNS	_	56	nsubj
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	61.7	61.7	CD	_	45	nummod
45	%	%	NN	_	42	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	and	and	CC	_	42	cc
48	1,375	1,375	CD	_	49	nummod
49	controls	control	NNS	_	42	conj
50	-LRB-	-lrb-	-LRB-	_	52	punct
51	87.1	87.1	CD	_	52	nummod
52	%	%	NN	_	49	appos
53	-RRB-	-rrb-	-RRB-	_	52	punct
54	were	be	VBD	_	56	cop
55	never	never	RB	_	56	neg
56	smokers	smoker	NNS	_	33	acl:relcl
57	.	.	.	_	3	punct

1	The	the	DT	_	5	det
2	COMT	COMT	NNP	_	5	compound
3	drug1	drug1	NN	_	5	compound
4	A	a	DT	_	5	det
5	allele	allele	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	positively	positively	RB	_	8	advmod
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	in	in	IN	_	13	case
12	never	never	RB	_	13	neg
13	smokers	smoker	NNS	_	8	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	for	for	IN	_	16	case
16	G/A	g/a	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	A/A	a/a	NN	_	16	conj
19	vs.	vs.	CC	_	16	cc
20	G/G	g/g	NN	_	16	conj
21	,	,	,	_	16	punct
22	OR	or	NN	_	16	conj
23	=	=	JJ	_	22	amod
24	1.46	1.46	CD	_	23	dep
25	,	,	,	_	16	punct
26	95	95	CD	_	27	compound
27	%	%	NN	_	28	amod
28	CI	ci	NN	_	16	conj
29	:	:	:	_	16	punct
30	1.12	1.12	CD	_	16	dep
31	,	,	,	_	30	punct
32	1.90	1.90	CD	_	30	conj
33	-RRB-	-rrb-	-RRB-	_	16	punct
34	but	but	CC	_	13	cc
35	not	not	RB	_	38	neg
36	in	in	IN	_	38	case
37	ever	ever	RB	_	38	advmod
38	smokers	smoker	NNS	_	13	conj
39	.	.	.	_	8	punct

1	Thus	thus	RB	_	4	advmod
2	,	,	,	_	4	punct
3	we	we	PRP	_	4	nsubj
4	hypothesized	hypothesize	VBD	_	0	ROOT
5	that	that	IN	_	12	mark
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	1	1	LS	_	12	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	the	the	DT	_	11	det
10	COMT	COMT	NNP	_	11	compound
11	gene	gene	NN	_	12	nsubj
12	contributes	contribute	VBZ	_	4	ccomp
13	to	to	TO	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	12	cc
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	2	2	LS	_	21	dep
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	a	a	DT	_	21	det
20	COMT	COMT	NNP	_	21	compound
21	polymorphism	polymorphism	NN	_	32	nsubj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug1	drug1	NN	_	21	dep
24	:	:	:	_	23	punct
25	Val158Met	val158met	NN	_	23	dep
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	causing	cause	VBG	_	21	acl
28	thermolability	thermolability	NN	_	27	dobj
29	of	of	IN	_	31	case
30	enzymatic	enzymatic	JJ	_	31	amod
31	activity	activity	NN	_	28	nmod
32	affects	affect	VBZ	_	12	conj
33	liver	liver	NN	_	34	compound
34	enzymes	enzyme	NNS	_	32	dobj
35	-LRB-	-lrb-	-LRB-	_	39	punct
36	e.g.	e.g.	FW	_	39	dep
37	,	,	,	_	39	punct
38	aspartate	aspartate	NN	_	39	compound
39	aminotransferase	aminotransferase	NN	_	34	dep
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	AST	AST	NNP	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	,	,	,	_	39	punct
44	alanine	alanine	NN	_	45	compound
45	aminotransferase	aminotransferase	NN	_	39	conj
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	ALT	alt	NN	_	45	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	and	and	CC	_	39	cc
50	gamma-glutamyl	gamma-glutamyl	NN	_	51	compound
51	transpeptidase	transpeptidase	NN	_	39	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	-GT	-gt	NN	_	51	appos
54	-RRB-	-rrb-	-RRB-	_	53	punct
55	-RRB-	-rrb-	-RRB-	_	39	punct
56	in	in	IN	_	57	case
57	serum	serum	NN	_	34	nmod
58	.	.	.	_	4	punct

1	Recently	recently	RB	_	3	advmod
2	we	we	PRP	_	3	nsubj
3	identified	identify	VBD	_	0	ROOT
4	two	two	CD	_	5	nummod
5	SNPs	snp	NNS	_	3	dobj
6	in	in	IN	_	7	case
7	COMT	COMT	NNP	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	dep
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	that	that	WDT	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	associated	associate	VBN	_	5	acl:relcl
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	in	in	IN	_	21	case
19	an	a	DT	_	21	det
20	Australian	australian	JJ	_	21	amod
21	cohort	cohort	NN	_	17	nmod
22	.	.	.	_	3	punct

1	Individuals	individual	NNS	_	9	nsubj
2	with	with	IN	_	3	case
3	drug3	drug3	NN	_	1	nmod
4	were	be	VBD	_	9	cop
5	more	more	JJR	_	7	advmod
6	than	than	IN	_	5	mwe
7	twice	twice	RB	_	9	advmod
8	as	as	RB	_	9	advmod
9	likely	likely	JJ	_	0	ROOT
10	to	to	TO	_	11	mark
11	carry	carry	VB	_	9	xcomp
12	the	the	DT	_	14	det
13	GG	gg	NNS	_	14	compound
14	genotype	genotype	NN	_	11	dobj
15	compared	compare	VBN	_	19	case
16	to	to	TO	_	19	case
17	the	the	DT	_	19	det
18	AA	aa	NN	_	19	compound
19	genotype	genotype	NN	_	11	advcl
20	for	for	IN	_	23	case
21	both	both	CC	_	23	cc:preconj
22	the	the	DT	_	23	dep
23	drug1	drug1	NN	_	19	nmod
24	and	and	CC	_	23	cc
25	drug2	drug2	NN	_	26	compound
26	SNPs	snp	NNS	_	23	conj
27	.	.	.	_	9	punct

1	Association	Association	NNP	_	18	nsubjpass
2	of	of	IN	_	4	case
3	both	both	DT	_	4	cc:preconj
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	8	compound
7	withsubstance	withsubstance	NN	_	8	compound
8	dependence	dependence	NN	_	4	conj
9	,	,	,	_	4	punct
10	a	a	DT	_	12	det
11	common	common	JJ	_	12	amod
12	comorbidity	comorbidity	NN	_	4	appos
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	investigated	investigate	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	SNP	snp	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	associated	associate	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	SNP	snp	NN	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	a	a	DT	_	7	det
6	weak	weak	JJ	_	7	amod
7	association	association	NN	_	4	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	at	at	IN	_	13	case
11	the	the	DT	_	13	det
12	allele	allele	NN	_	13	compound
13	level	level	NN	_	7	nmod
14	that	that	WDT	_	17	nsubj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	reach	reach	VB	_	7	acl:relcl
18	significance	significance	NN	_	17	dobj
19	at	at	IN	_	22	case
20	the	the	DT	_	22	det
21	genotype	genotype	NN	_	22	compound
22	level	level	NN	_	17	nmod
23	but	but	CC	_	17	cc
24	it	it	PRP	_	27	nsubjpass
25	was	be	VBD	_	27	auxpass
26	not	not	RB	_	27	neg
27	associated	associate	VBN	_	17	conj
28	with	with	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	.	.	.	_	4	punct

1	Analysis	analysis	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	haplotypes	haplotype	NNS	_	1	nmod
5	also	also	RB	_	6	advmod
6	revealed	reveal	VBD	_	0	ROOT
7	association	association	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	with	with	IN	_	18	mark
11	the	the	DT	_	12	det
12	G/Ghaplotype	g/ghaplotype	NN	_	18	nsubj
13	being	be	VBG	_	18	cop
14	almost	almost	RB	_	16	advmod
15	1.5	1.5	CD	_	16	compound
16	times	time	NNS	_	18	dep
17	more	more	RBR	_	16	advmod
18	common	common	JJ	_	7	advcl
19	in	in	IN	_	21	case
20	drug3	drug3	NN	_	21	compound
21	cases	case	NNS	_	18	nmod
22	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	possible	possible	JJ	_	0	ROOT
4	that	that	IN	_	3	dep
5	the	the	DT	_	7	det
6	drug1	drug1	NN	_	7	compound
7	SNP	snp	NN	_	4	dep
8	,	,	,	_	7	punct
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	root
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	10	punct
14	results	result	VBZ	_	13	root
15	in	in	IN	_	19	case
16	a	a	DT	_	19	det
17	common	common	JJ	_	19	amod
18	molecular	molecular	JJ	_	19	amod
19	variant	variant	NN	_	14	nmod
20	of	of	IN	_	21	case
21	COMT	COMT	NNP	_	19	nmod
22	that	that	WDT	_	23	nsubj
23	contributes	contribute	VBZ	_	19	acl:relcl
24	to	to	TO	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug4	drug4	NN	_	28	compound
28	susceptibility	susceptibility	NN	_	25	conj
29	.	.	.	_	14	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	when	when	WRB	_	7	advmod
4	this	this	DT	_	5	det
5	relation	relation	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	assessed	assess	VBN	_	2	root
8	within	within	IN	_	9	case
9	strata	strata	NN	_	7	nmod
10	based	base	VBN	_	13	case
11	on	on	IN	_	13	case
12	estrogen-related	estrogen-related	JJ	_	13	amod
13	factors	factor	NNS	_	9	nmod
14	,	,	,	_	13	punct
15	a	a	DT	_	17	det
16	few	few	JJ	_	17	amod
17	SNPs	snp	NNS	_	13	appos
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	HSD17B1	hsd17b1	NN	_	17	dep
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug1	drug1	NN	_	19	dep
22	,	,	,	_	21	punct
23	drug2	drug2	NN	_	21	conj
24	and	and	CC	_	21	cc
25	drug3	drug3	NN	_	21	conj
26	-RRB-	-rrb-	-RRB-	_	21	punct
27	,	,	,	_	19	punct
28	COMT	comt	NN	_	19	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	drug4	drug4	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	,	,	,	_	19	punct
33	UGT1A1	ugt1a1	NN	_	19	conj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	drug5	drug5	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	and	and	CC	_	19	cc
38	ESR1	esr1	NN	_	19	conj
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug6	drug6	NN	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	seemed	seem	VBD	_	19	dep
43	to	to	TO	_	45	mark
44	be	be	VB	_	45	auxpass
45	related	relate	VBN	_	42	xcomp
46	to	to	TO	_	47	mark
47	drug7	drug7	VB	_	45	xcomp
48	in	in	IN	_	51	case
49	the	the	DT	_	51	det
50	same	same	JJ	_	51	amod
51	direction	direction	NN	_	47	nmod
52	of	of	IN	_	54	case
53	their	they	PRP$	_	54	nmod:poss
54	associations	association	NNS	_	51	nmod
55	with	with	IN	_	56	case
56	drug8	drug8	NN	_	54	nmod
57	.	.	.	_	7	punct

1	we	we	PRP	_	2	nsubj
2	examined	examine	VBD	_	0	ROOT
3	variations	variation	NNS	_	2	dobj
4	in	in	IN	_	9	case
5	maternal	maternal	JJ	_	9	amod
6	and	and	CC	_	5	cc
7	fetal	fetal	JJ	_	5	conj
8	COMT	comt	NN	_	9	compound
9	genes	gene	NNS	_	3	nmod
10	and	and	CC	_	3	cc
11	their	they	PRP$	_	12	nmod:poss
12	association	association	NN	_	3	conj
13	with	with	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	19	punct
16	term	term	NN	_	19	compound
17	vs	vs	CC	_	16	cc
18	preterm	preterm	NN	_	16	conj
19	pregnancies	pregnancy	NNS	_	14	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	using	use	VBG	_	2	xcomp
22	4	4	CD	_	24	nummod
23	functional	functional	JJ	_	24	amod
24	SNPs	snp	NNS	_	21	dobj
25	:	:	:	_	24	punct
26	drug1	drug1	NN	_	24	dep
27	,	,	,	_	26	punct
28	drug2	drug2	NN	_	26	conj
29	,	,	,	_	26	punct
30	drug3	drug3	NN	_	26	conj
31	,	,	,	_	26	punct
32	and	and	CC	_	26	cc
33	drug4	drug4	NN	_	26	conj
34	in	in	IN	_	36	case
35	both	both	CC	_	36	cc:preconj
36	AA	aa	NN	_	26	nmod
37	and	and	CC	_	36	cc
38	Cau	cau	NN	_	36	conj
39	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	conclusion	conclusion	NN	_	6	nmod
3	,	,	,	_	6	punct
4	our	we	PRP$	_	5	nmod:poss
5	study	study	NN	_	6	nsubj
6	demonstrated	demonstrate	VBD	_	0	ROOT
7	that	that	IN	_	20	mark
8	a	a	DT	_	10	det
9	synonymous	synonymous	JJ	_	10	amod
10	polymorphism	polymorphism	NN	_	20	nsubjpass
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	in	in	IN	_	17	case
14	the	the	DT	_	17	det
15	fetal	fetal	JJ	_	17	amod
16	COMT	comt	NN	_	17	compound
17	gene	gene	NN	_	12	nmod
18	,	,	,	_	10	punct
19	is	be	VBZ	_	20	auxpass
20	associated	associate	VBN	_	6	ccomp
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	in	in	IN	_	24	case
24	AA	aa	NN	_	22	nmod
25	.	.	.	_	6	punct

1	Variants	variant	NNS	_	9	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	drug2	drug2	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	were	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	the	the	DT	_	12	det
12	risk	risk	NN	_	9	nmod
13	of	of	IN	_	14	mark
14	developing	develop	VBG	_	12	acl
15	drug4	drug4	NN	_	14	dobj
16	.	.	.	_	9	punct

1	A	a	DT	_	4	det
2	common	common	JJ	_	4	amod
3	C-G-C-C-G-A	c-g-c-c-g-a	NN	_	4	compound
4	haplotype	haplotype	NN	_	17	nsubj
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-	-	:	_	6	punct
8	drug2	drug2	NN	_	6	dep
9	-	-	:	_	6	punct
10	drug3	drug3	NN	_	6	dep
11	-	-	:	_	6	punct
12	drug4	drug4	NN	_	6	dep
13	-	-	:	_	6	punct
14	drug5	drug5	NN	_	6	dep
15	-	-	:	_	6	punct
16	drug6	drug6	NN	_	6	dep
17	showed	show	VBD	_	0	ROOT
18	an	a	DT	_	20	det
19	inverse	inverse	JJ	_	20	amod
20	association	association	NN	_	17	dobj
21	with	with	IN	_	23	case
22	drug7	drug7	NN	_	23	compound
23	risk	risk	NN	_	20	nmod
24	in	in	IN	_	26	case
25	Hispanic	hispanic	JJ	_	26	amod
26	Caucasians	caucasian	NNS	_	20	nmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	OR	or	NN	_	26	dep
29	=	=	JJ	_	28	amod
30	0.19	0.19	CD	_	29	dep
31	,	,	,	_	28	punct
32	P	p	NN	_	33	nsubj
33	=	=	JJ	_	28	dep
34	0.04	0.04	CD	_	33	dobj
35	,	,	,	_	28	punct
36	95	95	CD	_	37	compound
37	%	%	NN	_	38	amod
38	CI	ci	NN	_	28	appos
39	=	=	JJ	_	38	amod
40	0.04-0	0.04-0	CD	_	41	nummod
41	.95	.95	CD	_	39	dep
42	-RRB-	-rrb-	-RRB-	_	28	punct
43	and	and	CC	_	26	cc
44	with	with	IN	_	47	case
45	aggressive	aggressive	JJ	_	47	amod
46	disease	disease	NN	_	47	compound
47	status	status	NN	_	26	conj
48	-LRB-	-lrb-	-LRB-	_	51	punct
49	i.e.	i.e.	FW	_	51	dep
50	Gleason	gleason	FW	_	51	compound
51	score	score	NN	_	47	dep
52	>	>	JJR	_	51	dep
53	or	or	CC	_	52	cc
54	=	=	JJ	_	52	conj
55	7	7	CD	_	52	dep
56	-RRB-	-rrb-	-RRB-	_	51	punct
57	in	in	IN	_	60	case
58	non-Hispanic	non-hispanic	JJ	_	60	amod
59	Caucasian	caucasian	JJ	_	60	amod
60	cases	case	NNS	_	20	nmod
61	-LRB-	-lrb-	-LRB-	_	62	punct
62	OR	or	NN	_	60	dep
63	=	=	JJ	_	62	amod
64	0.64	0.64	CD	_	63	dep
65	,	,	,	_	62	punct
66	P	p	NN	_	67	nsubj
67	=	=	JJ	_	62	dep
68	0.008	0.008	CD	_	67	dobj
69	,	,	,	_	62	punct
70	95	95	CD	_	71	compound
71	%	%	NN	_	72	amod
72	CI	ci	NN	_	62	appos
73	=	=	JJ	_	72	amod
74	0.47-0	0.47-0	CD	_	75	nummod
75	.89	.89	CD	_	73	dep
76	-RRB-	-rrb-	-RRB-	_	62	punct
77	.	.	.	_	17	punct

1	A	a	DT	_	2	det
2	subset	subset	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	82	82	CD	_	5	nummod
5	patients	patient	NNS	_	2	nmod
6	also	also	RB	_	7	advmod
7	underwent	undergo	VBD	_	0	ROOT
8	drug8	drug8	NN	_	9	compound
9	testing	testing	NN	_	7	dobj
10	,	,	,	_	7	punct
11	Patients	patient	NNS	_	13	nsubjpass
12	were	be	VBD	_	13	auxpass
13	genotyped	genotype	VBN	_	7	parataxis
14	for	for	IN	_	17	case
15	the	the	DT	_	17	det
16	MTHFR	mthfr	NN	_	17	compound
17	677C	677c	NN	_	13	nmod
18	>	>	JJR	_	21	amod
19	T	t	NN	_	21	compound
20	drug1	drug1	NN	_	21	compound
21	drug2	drug2	NN	_	17	dep
22	,	,	,	_	21	punct
23	MTR	mtr	NN	_	24	compound
24	2756A	2756a	NN	_	21	appos
25	>	>	JJR	_	29	advmod
26	G	g	NN	_	29	compound
27	drug3	drug3	NN	_	29	compound
28	MTRR	mtrr	NN	_	29	compound
29	203A	203a	NN	_	24	nmod
30	>	>	JJR	_	32	amod
31	G	g	NN	_	32	compound
32	drug4	drug4	NN	_	29	dep
33	,	,	,	_	32	punct
34	FOLH1	folh1	NN	_	35	compound
35	484T	484t	NN	_	32	conj
36	>	>	JJR	_	38	amod
37	C	c	NN	_	38	compound
38	drug5	drug5	NN	_	35	dep
39	,	,	,	_	32	punct
40	RFC	RFC	NNP	_	44	compound
41	80A	80a	CD	_	40	nummod
42	>	>	JJR	_	44	amod
43	G	g	NN	_	44	compound
44	drug6	drug6	NN	_	32	conj
45	and	and	CC	_	32	cc
46	COMT675G	comt675g	NN	_	50	compound
47	>	>	JJR	_	50	advmod
48	A	a	DT	_	50	det
49	drug7	drug7	NN	_	50	compound
50	polymorphisms	polymorphism	NNS	_	32	conj
51	.	.	.	_	7	punct

1	A	a	DT	_	3	det
2	common	common	JJ	_	3	amod
3	Val	val	NN	_	23	nsubj
4	-	-	:	_	3	punct
5	>	>	JJR	_	7	compound
6	Met	Met	NNP	_	7	compound
7	polymorphism	polymorphism	NN	_	3	dep
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	COMT	COMT	NNP	_	14	compound
14	gene	gene	NN	_	3	nmod
15	,	,	,	_	3	punct
16	associated	associate	VBN	_	3	acl
17	with	with	IN	_	21	case
18	increased	increase	VBN	_	21	amod
19	prefrontal	prefrontal	JJ	_	21	amod
20	dopamine	dopamine	NN	_	21	compound
21	catabolism	catabolism	NN	_	16	nmod
22	,	,	,	_	3	punct
23	impairs	impair	VBZ	_	0	ROOT
24	prefrontal	prefrontal	JJ	_	25	amod
25	cognition	cognition	NN	_	23	dobj
26	and	and	CC	_	23	cc
27	might	might	MD	_	28	aux
28	increase	increase	VB	_	23	conj
29	risk	risk	NN	_	28	dobj
30	for	for	IN	_	31	case
31	drug2	drug2	NN	_	29	nmod
32	.	.	.	_	23	punct

1	We	we	PRP	_	4	nsubj
2	have	have	VBP	_	4	aux
3	previously	previously	RB	_	4	advmod
4	found	find	VBN	_	0	ROOT
5	an	a	DT	_	6	det
6	association	association	NN	_	4	dobj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	11	compound
11	addiction	addiction	NN	_	8	conj
12	.	.	.	_	4	punct

1	Our	we	PRP$	_	2	nmod:poss
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	12	mark
5	individual	individual	JJ	_	6	amod
6	susceptibility	susceptibility	NN	_	12	nsubjpass
7	to	to	TO	_	9	case
8	drug4	drug4	NN	_	9	compound
9	incidence	incidence	NN	_	6	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	increased	increase	VBN	_	3	ccomp
13	by	by	IN	_	15	case
14	combined	combined	JJ	_	15	amod
15	effects	effect	NNS	_	12	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	high-risk	high-risk	JJ	_	19	amod
19	genotypes	genotype	NNS	_	15	nmod
20	in	in	IN	_	21	case
21	drug1	drug1	NN	_	15	nmod
22	,	,	,	_	21	punct
23	drug2	drug2	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	drug3	drug3	NN	_	29	compound
27	estrogen	estrogen	NN	_	29	compound
28	metabolic	metabolic	JJ	_	29	amod
29	genes	gene	NNS	_	21	conj
30	.	.	.	_	3	punct

1	The	the	DT	_	6	det
2	Val108/158Met	val108/158met	NN	_	6	compound
3	drug1	drug1	NN	_	6	compound
4	single	single	JJ	_	6	amod
5	nucleotide	nucleotide	NN	_	6	compound
6	polymorphism	polymorphism	NN	_	17	nsubj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	SNP	snp	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	in	in	IN	_	16	case
11	the	the	DT	_	16	det
12	catechol-O-methyltransferase	catechol-o-methyltransferase	NN	_	16	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	COMT	comt	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	gene	gene	NN	_	6	nmod
17	contributes	contribute	VBZ	_	0	ROOT
18	to	to	TO	_	20	case
19	genetic	genetic	JJ	_	20	amod
20	susceptibility	susceptibility	NN	_	17	nmod
21	to	to	TO	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	,	,	,	_	22	punct
24	which	which	WDT	_	27	nsubj
25	is	be	VBZ	_	27	cop
26	specifically	specifically	RB	_	27	advmod
27	related	related	JJ	_	22	acl:relcl
28	to	to	TO	_	29	case
29	impairments	impairment	NNS	_	27	nmod
30	in	in	IN	_	32	case
31	executive	executive	NN	_	32	compound
32	functioning	functioning	NN	_	29	nmod
33	.	.	.	_	17	punct

1	A	a	DT	_	4	det
2	different	different	JJ	_	4	amod
3	genomic	genomic	JJ	_	4	amod
4	region	region	NN	_	22	nsubjpass
5	composed	compose	VBN	_	4	acl
6	of	of	IN	_	8	case
7	three	three	CD	_	8	nummod
8	SNPs	snp	NNS	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug1	drug1	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	appos
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	appos
15	-RRB-	-rrb-	-RRB-	_	10	punct
16	within	within	IN	_	19	case
17	the	the	DT	_	19	det
18	COMT	COMT	NNP	_	19	compound
19	gene	gene	NN	_	8	nmod
20	has	have	VBZ	_	22	aux
21	been	be	VBN	_	22	auxpass
22	reported	report	VBN	_	0	ROOT
23	to	to	TO	_	26	mark
24	be	be	VB	_	26	auxpass
25	significantly	significantly	RB	_	26	advmod
26	associated	associate	VBN	_	22	xcomp
27	with	with	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	in	in	IN	_	31	case
30	Ashkenazi	Ashkenazi	NNP	_	31	compound
31	Jews	Jews	NNPS	_	28	nmod
32	.	.	.	_	22	punct

1	The	the	DT	_	3	det
2	SNP	snp	NN	_	3	compound
3	drug1	drug1	NN	_	23	nsubjpass
4	,	,	,	_	3	punct
5	which	which	WDT	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	mapped	map	VBN	_	3	acl:relcl
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	3	3	CD	_	8	nmod
12	'	'	''	_	11	punct
13	-	-	:	_	11	punct
14	UTR	utr	NN	_	15	compound
15	region	region	NN	_	11	dep
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	COMT	COMT	NNP	_	19	compound
19	gene	gene	NN	_	15	nmod
20	,	,	,	_	3	punct
21	was	be	VBD	_	23	auxpass
22	significantly	significantly	RB	_	23	advmod
23	associated	associate	VBN	_	0	ROOT
24	with	with	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	in	in	IN	_	29	case
27	our	we	PRP$	_	29	nmod:poss
28	family	family	NN	_	29	compound
29	study	study	NN	_	25	nmod
30	,	,	,	_	23	punct
31	and	and	CC	_	23	cc
32	possibly	possibly	RB	_	33	advmod
33	associated	associate	VBN	_	23	conj
34	with	with	IN	_	36	case
35	the	the	DT	_	36	det
36	age	age	NN	_	33	nmod
37	of	of	IN	_	38	case
38	onset	onset	NN	_	36	nmod
39	,	,	,	_	23	punct
40	delusion/hallucination	delusion/hallucination	NN	_	42	compound
41	symptom	symptom	NN	_	42	compound
42	dimension	dimension	NN	_	39	root
43	,	,	,	_	42	punct
44	and	and	CC	_	42	cc
45	CPT	CPT	NNP	_	46	compound
46	performance	performance	NN	_	42	conj
47	.	.	.	_	42	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	COMT	COMT	NNP	_	5	nsubj
4	may	may	MD	_	5	aux
5	contribute	contribute	VB	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	genetic	genetic	JJ	_	9	amod
9	risk	risk	NN	_	5	nmod
10	for	for	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	not	not	RB	_	16	neg
13	through	through	IN	_	16	case
14	the	the	DT	_	16	det
15	drug1	drug1	NN	_	16	compound
16	polymorphism	polymorphism	NN	_	5	nmod
17	,	,	,	_	5	punct
18	but	but	CC	_	5	cc
19	through	through	IN	_	21	case
20	other	other	JJ	_	21	amod
21	variants	variant	NNS	_	5	conj
22	that	that	WDT	_	24	nsubjpass
23	are	be	VBP	_	24	auxpass
24	situated	situate	VBN	_	21	acl:relcl
25	3	3	CD	_	24	dobj
26	'	'	''	_	25	punct
27	to	to	TO	_	29	case
28	this	this	DT	_	29	det
29	region	region	NN	_	24	nmod
30	,	,	,	_	21	punct
31	in	in	IN	_	34	case
32	the	the	DT	_	34	det
33	Taiwanese	taiwanese	JJ	_	34	amod
34	population	population	NN	_	21	nmod
35	.	.	.	_	5	punct

1	OBJECTIVE	objective	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	T	t	NN	_	5	compound
5	allele	allele	NN	_	25	nsubj
6	of	of	IN	_	9	case
7	a	a	DT	_	9	det
8	functional	functional	JJ	_	9	amod
9	polymorphism	polymorphism	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	:	:	:	_	11	punct
13	LCT-13910	lct-13910	NN	_	14	compound
14	C	c	NN	_	11	dep
15	>	>	JJR	_	14	amod
16	T	t	NN	_	15	dep
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	,	,	,	_	5	punct
19	close	close	JJ	_	5	amod
20	to	to	TO	_	23	case
21	the	the	DT	_	23	det
22	lactase	lactase	NN	_	23	compound
23	gene	gene	NN	_	19	nmod
24	,	,	,	_	5	punct
25	correlates	correlate	VBZ	_	1	appos
26	with	with	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	LP	lp	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	in	in	IN	_	32	case
32	adults	adult	NNS	_	27	nmod
33	.	.	.	_	1	punct

1	Our	we	PRP$	_	2	nmod:poss
2	aim	aim	NN	_	3	nsubj
3	was	be	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	test	test	VB	_	3	xcomp
6	in	in	IN	_	8	case
7	this	this	DT	_	8	det
8	study	study	NN	_	5	nmod
9	,	,	,	_	3	punct
10	the	the	DT	_	11	det
11	association	association	NN	_	9	root
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	with	with	IN	_	15	case
15	BMI	bmi	NN	_	11	nmod
16	and	and	CC	_	15	cc
17	related	related	JJ	_	18	amod
18	drug2	drug2	NN	_	15	conj
19	,	,	,	_	11	punct
20	in	in	IN	_	21	case
21	interaction	interaction	NN	_	19	root
22	with	with	IN	_	25	case
23	dairy	dairy	NN	_	25	compound
24	product	product	NN	_	25	compound
25	consumption	consumption	NN	_	21	nmod
26	.	.	.	_	21	punct

1	drug2	drug2	NN	_	6	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	PLI	pli	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	was	be	VBD	_	6	auxpass
6	defined	define	VBN	_	0	ROOT
7	as	as	IN	_	10	case
8	the	the	DT	_	10	det
9	C/C	C/C	NNP	_	10	compound
10	genotype	genotype	NN	_	6	nmod
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	drug1	drug1	NN	_	14	compound
14	polymorphism	polymorphism	NN	_	10	nmod
15	.	.	.	_	6	punct

1	We	we	PRP	_	2	nsubj
2	hypothesized	hypothesize	VBD	_	0	ROOT
3	that	that	IN	_	17	mark
4	individuals	individual	NNS	_	17	nsubj
5	with	with	IN	_	8	case
6	the	the	DT	_	8	det
7	drug2	drug2	NN	_	8	compound
8	allele	allele	NN	_	4	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	LCT	LCT	NNP	_	12	compound
12	SNP	snp	NN	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug1	drug1	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	would	would	MD	_	17	aux
17	exhibit	exhibit	VB	_	2	ccomp
18	a	a	DT	_	20	det
19	greater	greater	JJR	_	20	amod
20	degree	degree	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	17	cc
24	that	that	IN	_	29	mark
25	this	this	DT	_	26	det
26	relationship	relationship	NN	_	29	nsubjpass
27	would	would	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	mediated	mediate	VBN	_	17	conj
30	by	by	IN	_	32	case
31	lactose	lactose	NN	_	32	compound
32	consumption	consumption	NN	_	29	nmod
33	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	C/T	c/t	NN	_	4	compound
3	-13910	-13910	CD	_	4	nummod
4	lactasevariant	lactasevariant	NN	_	9	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug1	drug1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	was	be	VBD	_	9	auxpass
9	genotyped	genotype	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	630	630	CD	_	12	nummod
12	men	man	NNS	_	9	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	12	cc
16	873	873	CD	_	19	nummod
17	matched	match	VBN	_	19	amod
18	control	control	NN	_	19	compound
19	participants	participant	NNS	_	12	conj
20	.	.	.	_	9	punct

1	The	the	DT	_	6	det
2	-13910	-13910	CD	_	6	nummod
3	C	c	NN	_	6	compound
4	>	>	JJR	_	6	amod
5	T	t	NN	_	6	compound
6	polymorphism	polymorphism	NN	_	30	nsubj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	upstream	upstream	RB	_	6	advmod
11	from	from	IN	_	17	case
12	the	the	DT	_	17	det
13	lactase	lactase	NN	_	17	compound
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	LCT	lct	NN	_	17	compound
16	-RRB-	-rrb-	-RRB-	_	17	punct
17	gene	gene	NN	_	10	nmod
18	,	,	,	_	6	punct
19	strongly	strongly	RB	_	20	advmod
20	associated	associate	VBN	_	6	acl
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	LP	lp	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	in	in	IN	_	27	case
27	Europeans	Europeans	NNPS	_	22	nmod
28	,	,	,	_	6	punct
29	is	be	VBZ	_	30	aux
30	emerging	emerge	VBG	_	0	ROOT
31	as	as	IN	_	34	case
32	a	a	DT	_	34	det
33	new	new	JJ	_	34	amod
34	candidate	candidate	NN	_	30	nmod
35	for	for	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	.	.	.	_	30	punct

1	In	in	IN	_	2	case
2	contrast	contrast	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	haplotypes	haplotype	NNS	_	3	root
5	at	at	IN	_	7	case
6	another	another	DT	_	7	det
7	block	block	NN	_	4	nmod
8	tagged	tag	VBN	_	7	acl
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	associated	associate	VBN	_	10	acl
12	with	with	IN	_	14	case
13	prevalent	prevalent	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	b	b	NN	_	14	dep
17	=	=	JJ	_	16	amod
18	0.239	0.239	CD	_	17	dep
19	,	,	,	_	16	punct
20	p	p	NN	_	24	dep
21	=	=	JJ	_	24	dep
22	2.05	2.05	CD	_	24	nummod
23	*	*	SYM	_	24	dep
24	10	10	CD	_	16	dep
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	-4	-4	CD	_	24	dep
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	-RRB-	-rrb-	-RRB-	_	16	punct
29	,	,	,	_	4	punct
30	but	but	CC	_	4	cc
31	remarkably	remarkably	RB	_	35	advmod
32	these	these	DT	_	35	nsubjpass
33	are	be	VBP	_	35	auxpass
34	inversely	inversely	RB	_	35	advmod
35	associated	associate	VBN	_	4	conj
36	with	with	IN	_	38	case
37	disease	disease	NN	_	38	compound
38	severity	severity	NN	_	35	nmod
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	b	b	NN	_	38	dep
41	=	=	JJ	_	40	amod
42	-0.196	-0.196	CD	_	41	dep
43	,	,	,	_	40	punct
44	p	p	NN	_	45	nsubj
45	=	=	JJ	_	40	dep
46	0.003	0.003	CD	_	45	dobj
47	-RRB-	-rrb-	-RRB-	_	40	punct
48	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	20	nsubjpass
3	of	of	IN	_	9	case
4	four	four	CD	_	9	nummod
5	common	common	JJ	_	9	amod
6	oxytocin	oxytocin	NN	_	9	compound
7	receptor	receptor	NN	_	9	compound
8	gene	gene	NN	_	9	compound
9	polymorphisms	polymorphism	NNS	_	2	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	and	and	CC	_	11	cc
17	drug4	drug4	NN	_	11	conj
18	-RRB-	-rrb-	-RRB-	_	11	punct
19	was	be	VBD	_	20	auxpass
20	evaluated	evaluate	VBN	_	0	ROOT
21	in	in	IN	_	24	case
22	one	one	CD	_	23	compound
23	hundred	hundred	CD	_	24	nummod
24	women	woman	NNS	_	20	nmod
25	with	with	IN	_	26	case
26	drug5	drug5	NN	_	24	nmod
27	and	and	CC	_	24	cc
28	one	one	CD	_	31	nummod
29	hundred	hundred	CD	_	31	nummod
30	healthy	healthy	JJ	_	31	amod
31	women	woman	NNS	_	24	conj
32	using	use	VBG	_	31	acl
33	restriction	restriction	NN	_	37	compound
34	fragment	fragment	NN	_	37	compound
35	length	length	NN	_	37	compound
36	polymorphism	polymorphism	NN	_	37	compound
37	genotyping	genotyping	NN	_	32	dobj
38	.	.	.	_	20	punct

1	In	in	IN	_	3	case
2	haplotype	haplotype	NN	_	3	compound
3	analysis	analysis	NN	_	21	nmod
4	,	,	,	_	21	punct
5	the	the	DT	_	7	det
6	haplotype	haplotype	NN	_	7	compound
7	combination	combination	NN	_	21	nsubjpass
8	of	of	IN	_	11	case
9	drug1	drug1	NN	_	11	compound
10	A	a	NN	_	11	compound
11	allele	allele	NN	_	7	nmod
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	15	compound
14	C	c	NN	_	15	compound
15	allele	allele	NN	_	11	conj
16	and	and	CC	_	11	cc
17	drug3	drug3	NN	_	19	compound
18	G	g	NN	_	19	compound
19	allele	allele	NN	_	11	conj
20	was	be	VBD	_	21	auxpass
21	found	find	VBN	_	0	ROOT
22	to	to	TO	_	25	mark
23	be	be	VB	_	25	auxpass
24	significantly	significantly	RB	_	25	advmod
25	associated	associate	VBN	_	21	xcomp
26	with	with	IN	_	29	case
27	an	a	DT	_	29	det
28	increased	increase	VBN	_	29	amod
29	risk	risk	NN	_	25	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	OR	or	NN	_	29	dep
34	=	=	JJ	_	33	amod
35	3.2	3.2	CD	_	34	dep
36	-LSB-	-lsb-	-LRB-	_	37	punct
37	CI	ci	NN	_	33	appos
38	1.04-9	1.04-9	CD	_	39	nummod
39	.8	.8	CD	_	37	nummod
40	-RSB-	-rsb-	-RRB-	_	37	punct
41	,	,	,	_	33	punct
42	p	p	NN	_	43	nsubj
43	=	=	JJ	_	33	dep
44	0.043	0.043	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	33	punct
46	.	.	.	_	21	punct

1	With	with	IN	_	5	case
2	respect	respect	NN	_	5	dep
3	to	to	TO	_	5	case
4	OXTR	oxtr	NN	_	5	compound
5	drug1	drug1	NN	_	12	nmod
6	,	,	,	_	12	punct
7	mothers	mother	NNS	_	12	nsubj
8	with	with	IN	_	11	case
9	the	the	DT	_	11	det
10	GG	gg	NNS	_	11	compound
11	genotype	genotype	NN	_	7	nmod
12	showed	show	VBD	_	0	ROOT
13	greater	greater	JJR	_	14	amod
14	drug2	drug2	NN	_	12	dobj
15	across	across	IN	_	17	case
16	varying	vary	VBG	_	17	amod
17	levels	level	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	interparental	interparental	JJ	_	20	amod
20	conflict	conflict	NN	_	17	nmod
21	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	aim	aim	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	study	study	NN	_	2	nmod
6	was	be	VBD	_	0	ROOT
7	to	to	TO	_	8	mark
8	investigate	investigate	VB	_	6	xcomp
9	whether	whether	IN	_	40	mark
10	a	a	DT	_	11	det
11	set	set	NN	_	40	nsubjpass
12	of	of	IN	_	15	case
13	single	single	JJ	_	15	amod
14	nucleotide	nucleotide	NN	_	15	compound
15	polymorphisms	polymorphism	NNS	_	11	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	SNPs	snp	NNS	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	within	within	IN	_	20	case
20	cyclooxygenase-2	cyclooxygenase-2	NN	_	15	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	COX-2	cox-2	NN	_	20	dep
23	,	,	,	_	22	punct
24	drug1	drug1	NN	_	22	conj
25	and	and	CC	_	22	cc
26	drug2	drug2	NN	_	22	conj
27	-RRB-	-rrb-	-RRB-	_	22	punct
28	and	and	CC	_	20	cc
29	oxytocin	oxytocin	NN	_	30	compound
30	receptor	receptor	NN	_	20	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	OXTR	oxtr	NN	_	30	dep
33	,	,	,	_	32	punct
34	drug3	drug3	NN	_	32	conj
35	and	and	CC	_	32	cc
36	drug4	drug4	NN	_	32	conj
37	-RRB-	-rrb-	-RRB-	_	32	punct
38	genes	gene	NNS	_	20	dep
39	was	be	VBD	_	40	auxpass
40	associated	associate	VBN	_	8	ccomp
41	with	with	IN	_	42	case
42	drug5	drug5	NN	_	40	nmod
43	,	,	,	_	42	punct
44	response	response	NN	_	42	conj
45	or	or	CC	_	42	cc
46	remission	remission	NN	_	42	conj
47	.	.	.	_	6	punct

1	For	for	IN	_	3	case
2	this	this	DT	_	3	det
3	purpose	purpose	NN	_	37	nmod
4	,	,	,	_	37	punct
5	two	two	CD	_	8	nummod
6	single	single	JJ	_	8	amod
7	nucleotide	nucleotide	NN	_	8	compound
8	polymorphisms	polymorphism	NNS	_	37	nsubjpass
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	SNPs	snp	NNS	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	8	punct
13	6930G	6930g	NN	_	8	appos
14	>	>	JJR	_	13	amod
15	A	a	NN	_	14	dep
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug1	drug1	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	15	cc
20	9073G	9073g	NN	_	15	conj
21	>	>	JJR	_	15	amod
22	A	a	NN	_	21	dep
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug2	drug2	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	8	punct
27	within	within	IN	_	31	case
28	the	the	DT	_	31	det
29	oxytocin	oxytocin	NN	_	31	compound
30	receptor	receptor	NN	_	31	compound
31	gene	gene	NN	_	8	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	OXTR	oxtr	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	,	,	,	_	8	punct
36	were	be	VBD	_	37	auxpass
37	studied	study	VBN	_	0	ROOT
38	in	in	IN	_	40	case
39	a	a	DT	_	40	det
40	cohort	cohort	NN	_	37	nmod
41	of	of	IN	_	43	case
42	185	185	CD	_	43	nummod
43	patients	patient	NNS	_	40	nmod
44	with	with	IN	_	46	case
45	major	major	JJ	_	46	amod
46	drug3	drug3	NN	_	43	nmod
47	-LRB-	-lrb-	-LRB-	_	49	punct
48	50.3	50.3	CD	_	49	nummod
49	%	%	NN	_	43	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	or	or	CC	_	43	cc
52	drug4	drug4	NN	_	56	compound
53	I	i	CD	_	56	nummod
54	or	or	CC	_	53	cc
55	II	ii	CD	_	53	conj
56	disorders	disorder	NNS	_	43	conj
57	-LRB-	-lrb-	-LRB-	_	59	punct
58	49.7	49.7	CD	_	59	nummod
59	%	%	NN	_	56	appos
60	-RRB-	-rrb-	-RRB-	_	59	punct
61	and	and	CC	_	43	cc
62	192	192	CD	_	65	nummod
63	matched	match	VBN	_	65	amod
64	healthy	healthy	JJ	_	65	amod
65	controls	control	NNS	_	43	conj
66	.	.	.	_	37	punct

1	A	a	DT	_	3	det
2	positive	positive	JJ	_	3	amod
3	association	association	NN	_	24	nsubjpass
4	between	between	IN	_	7	case
5	the	the	DT	_	7	det
6	GG	gg	NNS	_	7	compound
7	genotype	genotype	NN	_	3	nmod
8	of	of	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	SNPs	snp	NNS	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	6930G	6930g	NN	_	7	dep
13	>	>	JJR	_	18	advmod
14	A	a	DT	_	18	det
15	or	or	CC	_	14	cc
16	9073G	9073g	NN	_	14	conj
17	>	>	JJR	_	18	amod
18	A	a	NN	_	12	dep
19	-RRB-	-rrb-	-RRB-	_	12	punct
20	and	and	CC	_	7	cc
21	unipolar	unipolar	JJ	_	22	amod
22	drug2	drug2	NN	_	7	conj
23	was	be	VBD	_	24	auxpass
24	demonstrated	demonstrate	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	For	for	IN	_	2	case
2	drug1	drug1	NN	_	15	nmod
3	,	,	,	_	15	punct
4	overtransmission	overtransmission	NN	_	15	nsubjpass
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	G	g	NN	_	8	compound
8	allele	allele	NN	_	4	nmod
9	to	to	TO	_	10	case
10	probands	proband	NNS	_	4	nmod
11	with	with	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	disorder	disorder	NN	_	10	nmod
14	was	be	VBD	_	15	auxpass
15	found	find	VBN	_	0	ROOT
16	which	which	WDT	_	17	nsubj
17	contrasts	contrast	VBZ	_	15	ccomp
18	with	with	IN	_	20	case
19	the	the	DT	_	20	det
20	overtransmission	overtransmission	NN	_	17	nmod
21	of	of	IN	_	20	amod
22	A	a	DT	_	21	dep
23	previously	previously	RB	_	24	advmod
24	reported	report	VBN	_	22	acl
25	in	in	IN	_	29	case
26	the	the	DT	_	29	det
27	Chinese	chinese	JJ	_	29	amod
28	Han	han	NN	_	29	compound
29	sample	sample	NN	_	24	nmod
30	.	.	.	_	15	punct

1	RESULTS	result	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	6	det
4	family-based	family-based	JJ	_	6	amod
5	association	association	NN	_	6	compound
6	test	test	NN	_	10	nsubj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	FBAT	fbat	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	revealed	reveal	VBD	_	1	appos
11	a	a	DT	_	14	det
12	significant	significant	JJ	_	14	amod
13	genetic	genetic	JJ	_	14	amod
14	association	association	NN	_	10	dobj
15	between	between	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	two	two	CD	_	16	conj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	SNPs	snp	NNS	_	18	nmod
22	tested	test	VBN	_	21	acl
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	drug1	drug1	NN	_	25	compound
25	A	a	NN	_	21	dep
26	:	:	:	_	25	punct
27	Z	z	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	2.287	2.287	CD	_	28	dep
30	,	,	,	_	25	punct
31	p	p	NN	_	25	appos
32	=	=	JJ	_	31	amod
33	.0222	.0222	CD	_	32	dep
34	;	;	:	_	25	punct
35	drug2	drug2	NN	_	36	compound
36	A	a	NN	_	25	dep
37	:	:	:	_	36	punct
38	Z	z	NN	_	36	dep
39	=	=	JJ	_	38	amod
40	2.573	2.573	CD	_	39	dep
41	,	,	,	_	38	punct
42	p	p	NN	_	43	nsubj
43	=	=	JJ	_	38	dep
44	.0101	.0101	CD	_	43	dobj
45	-RRB-	-rrb-	-RRB-	_	25	punct
46	.	.	.	_	1	punct

1	When	when	WRB	_	4	advmod
2	haplotypes	haplotype	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	constructed	construct	VBN	_	17	advcl
5	with	with	IN	_	6	case
6	two	two	CD	_	4	nmod
7	,	,	,	_	6	punct
8	three	three	CD	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	four	four	CD	_	12	nummod
12	markers	marker	NNS	_	6	conj
13	,	,	,	_	17	punct
14	the	the	DT	_	16	det
15	haplotype-specific	haplotype-specific	JJ	_	16	amod
16	FBAT	fbat	NN	_	17	nsubj
17	revealed	reveal	VBD	_	0	ROOT
18	that	that	IN	_	31	mark
19	a	a	DT	_	20	det
20	number	number	NN	_	31	nsubjpass
21	of	of	IN	_	22	case
22	haplotypes	haplotype	NNS	_	20	nmod
23	,	,	,	_	20	punct
24	particularly	particularly	RB	_	25	advmod
25	those	those	DT	_	20	appos
26	involving	involve	VBG	_	25	acl
27	drug1	drug1	NN	_	26	dobj
28	,	,	,	_	20	punct
29	were	be	VBD	_	31	auxpass
30	significantly	significantly	RB	_	31	advmod
31	associated	associate	VBN	_	17	ccomp
32	with	with	IN	_	33	case
33	drug2	drug2	NN	_	31	nmod
34	.	.	.	_	17	punct

1	CONCLUSIONS	conclusion	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Our	we	PRP$	_	4	nmod:poss
4	meta-analysis	meta-analysis	NN	_	5	nsubj
5	suggests	suggest	VBZ	_	1	dep
6	that	that	IN	_	18	mark
7	the	the	DT	_	9	det
8	G	g	NN	_	9	compound
9	allele	allele	NN	_	18	nsubj
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	polymorphism	polymorphism	NN	_	9	nmod
13	might	might	MD	_	18	aux
14	be	be	VB	_	18	cop
15	a	a	DT	_	18	det
16	potential	potential	JJ	_	18	amod
17	risk	risk	NN	_	18	compound
18	factor	factor	NN	_	5	ccomp
19	for	for	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	,	,	,	_	18	punct
22	especially	especially	RB	_	24	advmod
23	in	in	IN	_	24	case
24	whitepopulations	whitepopulation	NNS	_	18	nmod
25	.	.	.	_	1	punct

1	The	the	DT	_	5	det
2	real-time	real-time	JJ	_	5	amod
3	polymerase	polymerase	NN	_	5	compound
4	chain	chain	NN	_	5	compound
5	reaction	reaction	NN	_	10	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	RT-PCR	rt-pcr	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	analyze	analyze	VB	_	10	xcomp
13	4	4	CD	_	14	nummod
14	SNPs	snp	NNS	_	12	dobj
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	drug1	drug1	NN	_	17	compound
17	A/G	a/g	NN	_	14	dep
18	,	,	,	_	17	punct
19	drug2	drug2	NN	_	20	compound
20	A/G	a/g	NN	_	17	conj
21	,	,	,	_	17	punct
22	drug3	drug3	NN	_	23	compound
23	A/G	a/g	NN	_	17	conj
24	,	,	,	_	17	punct
25	drug4	drug4	NN	_	26	compound
26	C/G	c/g	NN	_	17	appos
27	-RRB-	-rrb-	-RRB-	_	17	punct
28	in	in	IN	_	31	case
29	291	291	CD	_	31	nummod
30	drug5	drug5	NN	_	31	compound
31	patients	patient	NNS	_	12	nmod
32	and	and	CC	_	31	cc
33	247	247	CD	_	34	nummod
34	controls	control	NNS	_	31	conj
35	.	.	.	_	10	punct

1	Analysis	analysis	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	4	4	CD	_	4	nummod
4	SNPs	snp	NNS	_	1	nmod
5	revealed	reveal	VBD	_	0	ROOT
6	a	a	DT	_	8	det
7	significant	significant	JJ	_	8	amod
8	difference	difference	NN	_	5	dobj
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	genotype	genotype	NN	_	12	compound
12	distribution	distribution	NN	_	8	nmod
13	for	for	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	drug3	drug3	NN	_	14	conj
20	between	between	IN	_	22	case
21	drug5	drug5	CD	_	22	nummod
22	patients	patient	NNS	_	19	nmod
23	and	and	CC	_	22	cc
24	controls	control	NNS	_	22	conj
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	p	p	NN	_	27	nsubj
27	=	=	JJ	_	8	dep
28	0.041	0.041	CD	_	27	dobj
29	,	,	,	_	27	punct
30	p	p	NN	_	31	nsubj
31	=	=	JJ	_	27	parataxis
32	0.005	0.005	CD	_	31	dobj
33	,	,	,	_	27	punct
34	p	p	NN	_	35	nsubj
35	=	=	JJ	_	27	parataxis
36	0.023	0.023	CD	_	35	dobj
37	,	,	,	_	27	punct
38	respectively	respectively	RB	_	27	advmod
39	-RRB-	-rrb-	-RRB-	_	27	punct
40	but	but	CC	_	41	cc
41	not	not	RB	_	8	cc
42	for	for	IN	_	43	case
43	drug4	drug4	NN	_	8	conj
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	p	p	NN	_	46	nsubj
46	=	=	JJ	_	43	dep
47	0.211	0.211	CD	_	46	dobj
48	-RRB-	-rrb-	-RRB-	_	46	punct
49	.	.	.	_	5	punct

1	Minor	minor	JJ	_	2	amod
2	alleles	allele	NNS	_	5	nsubj
3	in	in	IN	_	4	case
4	three	three	CD	_	2	nmod
5	correlated	correlate	VBD	_	0	ROOT
6	ht	ht	NN	_	7	compound
7	SNPs	snp	NNS	_	25	nsubjpass
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug1	drug1	NN	_	7	dep
10	,	,	,	_	9	punct
11	,	,	,	_	9	punct
12	drug2	drug2	NN	_	9	conj
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	drug3	drug3	NN	_	9	conj
16	;	;	:	_	9	punct
17	r	r	NN	_	9	dep
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	2	2	CD	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	>	>	JJR	_	17	amod
22	0.6	0.6	CD	_	21	dep
23	-RRB-	-rrb-	-RRB-	_	9	punct
24	were	be	VBD	_	25	auxpass
25	associated	associate	VBN	_	5	ccomp
26	with	with	IN	_	28	case
27	increased	increase	VBN	_	28	amod
28	risk	risk	NN	_	25	nmod
29	for	for	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	.	.	.	_	5	punct

